0001628280-23-004698 | 10-K | XBRL Viewer

Print Document View Excel Document

Cover Page - USD ($) $ in Millions	12 Months Ended
Cover Page - USD ($) $ in Millions	Dec. 31, 2022	Feb. 16, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-36569
Entity Registrant Name	LANTHEUS HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	35-2318913
Entity Address, Address Line One	201 Burlington Road, South Building
Entity Address, City or Town	Bedford
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01730
City Area Code	978
Local Phone Number	671-8001
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	LNTH
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 4,487.0
Entity Common Stock, Shares Outstanding		67,540,065
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Listed hereunder are the documents, portions of which are incorporated by reference, and the parts of this Form 10-K into which such portions are incorporated: The Registrant’s Definitive Proxy Statement for use in connection with the Annual Meeting of Stockholders to be held on April 27, 2023, portions of which are incorporated by reference into Parts II and III of this Form 10-K. The 2023 Proxy Statement will be filed with the Securities and Exchange Commission no later than 120 days after the close of our year ended December 31, 2022.
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0001521036

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2022
Audit Information [Abstract]
Auditor Firm ID	34
Auditor Location	Boston, Massachusetts
Auditor Name	Deloitte & Touche LLP

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 415,652	$ 98,508
Accounts receivable, net	213,397	89,336
Inventory	35,475	35,129
Other current assets	13,092	12,818
Total current assets	677,616	235,791
Property, plant and equipment, net	122,166	116,772
Intangibles, net	315,285	348,510
Goodwill	61,189	61,189
Deferred tax assets, net	110,647	62,764
Other long-term assets	34,355	38,758
Total assets	1,321,258	863,784
Current liabilities
Current portion of long-term debt and other borrowings	354	11,642
Accounts payable	20,563	20,787
Short-term contingent liability	99,700	0
Accrued expenses and other liabilities	127,084	58,068
Total current liabilities	247,701	90,497
Asset retirement obligations	22,543	20,833
Long-term debt, net and other borrowings	557,712	163,121
Other long-term liabilities	46,155	124,894
Total liabilities	874,111	399,345
Commitments and contingencies (see Note 20)
Stockholders’ equity
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)	0	0
Common stock ($0.01 par value, 250,000 shares authorized; 68,851 and 67,739 shares issued as of December 31, 2022 and 2021, respectively)	689	677
Additional paid-in capital	715,875	685,472
Treasury Stock at cost - 1,339 and no shares as of December 31, 2022 and 2021, respectively	(75,000)	0
Accumulated deficit	(193,158)	(221,225)
Accumulated other comprehensive loss	(1,259)	(485)
Total stockholders’ equity	447,147	464,439
Total liabilities and stockholders’ equity	$ 1,321,258	$ 863,784

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	68,851,000	67,739,000
Treasury stock (in shares)	1,339,000	0

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenues	$ 935,061	$ 425,208	$ 339,410
Cost of goods sold	353,358	237,513	200,649
Gross profit	581,703	187,695	138,761
Operating expenses
Sales and marketing	100,243	68,422	40,901
General and administrative	133,584	150,395	69,270
Research and development	311,681	44,966	32,788
Total operating expenses	545,508	263,783	142,959
Gain on sales of assets	0	15,263	0
Operating income (loss)	36,195	(60,825)	(4,198)
Interest expense	7,185	7,752	9,479
Loss (gain) on extinguishment of debt	588	(889)	0
Other loss (income)	1,703	7,350	(2,198)
Income (loss) before income taxes	26,719	(75,038)	(11,479)
Income tax (benefit) expense	(1,348)	(3,759)	1,994
Net income (loss)	$ 28,067	$ (71,279)	$ (13,473)
Net income (loss) per common share:
Basic (in dollars per share)	$ 0.41	$ (1.06)	$ (0.25)
Diluted (in dollars per share)	$ 0.40	$ (1.06)	$ (0.25)
Weighted-average common shares outstanding:
Basic (in shares)	68,487	67,486	54,134
Diluted (in shares)	70,671	67,486	54,134

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 28,067	$ (71,279)	$ (13,473)
Other comprehensive income:
Foreign currency translation	(505)	(124)	330
Realized loss on cash flow hedges, net of tax	(269)	0	0
Unrealized gain (loss) on cash flow hedges, net of tax	0	1,687	(1,418)
Total other comprehensive (loss) income	(774)	1,563	(1,088)
Comprehensive income (loss)	$ 27,293	$ (69,716)	$ (14,561)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

Consolidated Statements of Changes in Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2019		39,251,000
Beginning balance (in shares) at Dec. 31, 2019			0
Beginning balance at Dec. 31, 2019	$ 114,601	$ 393	$ 0	$ 251,641	$ (136,473)	$ (960)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(13,473)				(13,473)
Other comprehensive (loss) income	(1,088)					(1,088)
Stock option exercises and employee stock plan purchases (in shares)		73,000
Stock option exercises and employee stock plan purchases	760	$ 1		759
Vesting of restricted stock awards (in shares)		847,000
Vesting of restricted stock awards	0	$ 8		(8)
Shares withheld to cover taxes (in shares)		(141,000)
Shares withheld to cover taxes	(2,129)	$ (2)		(2,127)
Issuance of common stock, net (in shares)		26,845,000
Issuance of common stock, net	394,334	$ 269		394,065
Fair value of replacement stock options related to precombination services	7,125			7,125
Stock-based compensation	14,075			14,075
Ending balance (in shares) at Dec. 31, 2020		66,875,000
Ending balance (in shares) at Dec. 31, 2020			0
Ending balance at Dec. 31, 2020	514,205	$ 669	$ 0	665,530	(149,946)	(2,048)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(71,279)				(71,279)
Other comprehensive (loss) income	1,563					1,563
Stock option exercises and employee stock plan purchases (in shares)		360,000
Stock option exercises and employee stock plan purchases	6,062	$ 3		6,059
Vesting of restricted stock awards (in shares)		611,000
Vesting of restricted stock awards	0	$ 6		(6)
Shares withheld to cover taxes (in shares)		(107,000)
Shares withheld to cover taxes	(2,046)	$ (1)		(2,045)
Stock-based compensation	$ 15,934			15,934
Ending balance (in shares) at Dec. 31, 2021		67,739,000
Ending balance (in shares) at Dec. 31, 2021	0		0
Ending balance at Dec. 31, 2021	$ 464,439	$ 677	$ 0	685,472	(221,225)	(485)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	28,067				28,067
Other comprehensive (loss) income	(774)					(774)
Stock option exercises and employee stock plan purchases (in shares)		411,000
Stock option exercises and employee stock plan purchases	8,912	$ 4		8,908
Vesting of restricted stock awards (in shares)		845,000
Vesting of restricted stock awards	0	$ 9		(9)
Shares withheld to cover taxes (in shares)		(144,000)
Shares withheld to cover taxes	(7,759)	$ (1)		(7,758)
Repurchase of common stock (in shares)			1,339,000
Repurchase of common stock	(75,000)		$ (75,000)
Stock-based compensation	$ 29,262			29,262
Ending balance (in shares) at Dec. 31, 2022		68,851,000
Ending balance (in shares) at Dec. 31, 2022	1,339,000		1,339,000
Ending balance at Dec. 31, 2022	$ 447,147	$ 689	$ (75,000)	$ 715,875	$ (193,158)	$ (1,259)

Consolidated Statements of Changes in Stockholders’ Equity (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 3,776

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Net income (loss)	$ 28,067	$ (71,279)	$ (13,473)
Adjustments to reconcile net income (loss) to net cash flows from operating activities:
Depreciation, amortization and accretion	47,929	42,288	24,689
Impairment of long-lived assets	0	9,729	9,935
Asset retirement obligation acceleration	280	5,259	0
Gain on interest rate swap termination	(5,494)	0	0
Amortization of debt related costs	1,249	676	119
Changes in fair value of contingent assets and liabilities	34,700	72,400	(2,000)
Charges incurred in connection with acquired IPR&D	260,000	0	0
Loss (gain) on extinguishment of debt	588	(889)	0
Provision for excess and obsolete inventory	7,145	4,057	2,365
Stock-based compensation	29,262	15,934	14,075
(Gain) loss on disposal of assets	0	(15,263)	2,250
Deferred taxes	(48,016)	4,437	(1,334)
Long-term indemnification receivable	9,554	7,121	(2,218)
Long-term income tax payable and other long-term liabilities	(12,477)	(7,912)	2,828
Other	4,059	2,512	1,525
Increases (decreases) in cash from operating assets and liabilities:
Accounts receivable	(128,460)	(33,102)	(7,462)
Inventory	(7,508)	(3,549)	(8,459)
Other current assets	(2,440)	(73)	1,941
Other long-term assets	(533)	0	0
Accounts payable	301	5,425	(4,224)
Accrued expenses and other liabilities	63,575	16,145	(4,161)
Net cash provided by operating activities	281,781	53,916	16,396
Investing activities
Capital expenditures	(18,347)	(12,140)	(12,474)
Proceeds from sale of assets, net	1,800	15,823	0
Acquisition of assets	(260,000)	0	0
Lending on bridge loan	0	0	(10,000)
Cash acquired in acquisition of business	0	0	17,562
Net cash (used in) provided by investing activities	(276,547)	3,683	(4,912)
Financing activities
Proceeds from issuance of common stock	1,375	767	683
Equity issuance costs	0	0	(3,777)
Debt issuance costs	(95)	0	0
Proceeds from issuance of long-term debt, net	557,750	0	0
Payments on long-term debt and other borrowings	(175,385)	(43,348)	(15,491)
Deferred financing costs	(2,315)	0	(1,224)
Proceeds from interest rate swap termination	5,583	0	0
Proceeds from stock option exercises	7,537	5,295	77
Payments for minimum statutory tax withholding related to net share settlement of equity awards	(7,759)	(2,046)	(2,129)
Repurchase of common stock	(75,000)	0	0
Net cash provided by (used in) financing activities	311,691	(39,332)	(21,861)
Effect of foreign exchange rates on cash and cash equivalents	(335)	(310)	152
Net increase (decrease) in cash and cash equivalents and restricted cash	316,590	17,957	(10,225)
Cash and cash equivalents and restricted cash, beginning of year	100,651	82,694	92,919
Cash and cash equivalents and restricted cash, end of year	417,241	100,651	82,694
Reconciliation to amounts within the consolidated balance sheets
Cash and cash equivalents	415,652	98,508	79,612
Cash and cash equivalents included in assets held for sale	0	0	941
Restricted cash included in other long-term assets	1,589	2,143	2,141
Cash, cash equivalents and restricted cash at end of period	417,241	100,651	82,694
Supplemental disclosure of cash flow information
Interest	5,064	6,284	9,368
Income taxes, net of refunds of $50, $315 and $331, respectively	54,049	215	340
Schedule of non-cash investing and financing activities
Additions of property, plant and equipment included in liabilities	2,370	1,262	2,227
Consideration transferred in acquisition	$ 0	$ 0	$ 419,009

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Cash Flows [Abstract]
Proceeds from income tax refunds	$ 50	$ 315	$ 331

Description of Business	12 Months Ended
Description of Business	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Lantheus Holdings, Inc., a Delaware corporation, is the parent company of Lantheus Medical Imaging, Inc. (“LMI”) and LMI is the parent company of Progenics Pharmaceuticals, Inc., a Delaware corporation (“Progenics”). See “Progenics Acquisition”. The Company develops, manufactures and commercializes innovative diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of cancer, heart disease and other diseases. The Company believes its diagnostic products result in improved diagnostic information that enables healthcare providers to better detect and characterize, or rule out, disease, potentially achieving improved patient outcomes, reducing patient risk and limiting overall costs throughout the healthcare system. The Company’s commercial products are used by oncologists, urologists, nuclear medicine physicians, cardiologists, sonographers, technologists, radiologists, and internal medicine physicians working in a variety of clinical settings. The Company produces and markets its products throughout the U.S., selling primarily to hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, and group practices. The Company sells its products outside the U.S. through a combination of direct distribution in Canada and third party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America and South America. Sales of the Company’s prostate cancer diagnostic imaging agent, PYLARIFY (as defined below), are generated in the U.S. through a PYLARIFY direct sales team and a sales team at some of our positron emission tomography (“PET”) manufacturing facilities (“PMF”) partners. Sales of the Company’s ultrasound enhancing agent, DEFINITY, are generated in the U.S. and Canada through a DEFINITY direct sales team. In the U.S., the Company’s other nuclear imaging products, including TechneLite, Xenon, NEUROLITE and CARDIOLITE, are primarily sold to commercial radiopharmacies, the majority of which are controlled by or associated with Cardinal, RLS, UPPI, PharmaLogic and Jubilant Radiopharma. A small portion of the Company’s nuclear imaging product sales in the U.S. are generated through the Company’s direct sales force to hospitals and clinics that maintain their own in-house radiopharmaceutical preparation capabilities. We have licensed RELISTOR to Bausch, and the Company collects quarterly royalties based on those sales. AZEDRA sales are generated in the U.S. through an AZEDRA direct sales team. The Company also maintains its own direct sales force in Canada for certain of its products. In Europe, Australia, Asia-Pacific, Central America and South America, the Company generally relies on third party distributors to market, sell and distribute its nuclear imaging and ultrasound enhancing agent products, either on a country-by-country basis or on a multi-country regional basis. The Company’s executive offices are located in Bedford, MA, with additional offices in North Billerica, MA, Somerset, NJ, Montreal, Canada and Lund, Sweden. Progenics Acquisition On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Holdings (“Merger Sub”), and Progenics, Holdings completed the acquisition of Progenics by means of a merger of Merger Sub with and into Progenics, with Progenics surviving such merger as a wholly-owned subsidiary of Holdings (the “Progenics Acquisition”). In accordance with the Merger Agreement, at the effective time of the Progenics Acquisition (the “Effective Time”), each share of Progenics common stock, par value $0.0013 per share, issued and outstanding immediately prior to the Effective Time (other than shares of Progenics common stock owned by Holdings, Progenics or any of their wholly-owned subsidiaries) was automatically cancelled and converted into the right to receive (i) 0.31 (the “Exchange Ratio”) of a share of Holdings common stock, par value $0.01 per share, and (ii) one contingent value right (a “CVR”) tied to the financial performance of PyL (18F-DCFPyL), Progenics’ prostate-specific membrane antigen (“PSMA”) targeted imaging agent designed to visualize prostate cancer. This agent was approved by the U.S. Food and Drug Administration (“FDA”) on May 26, 2021 under the name PYLARIFY (piflufolastat F 18), and the commercial launch of this agent began in June 2021. Each CVR entitles its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively. In no event will the Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, exceed 19.9% of the total consideration the Company pays in the Progenics Acquisition. Based on the Company’s 2022 PYLARIFY net sales, the Company determined that the aggregate payment obligation under the CVRs was $99.7 million. The Company expects to make that payment during the first half of 2023. As a result of the acquisition, Holdings issued 26,844,877 shares of Holdings common stock and 86,630,633 CVRs to former Progenics stockholders and option holders.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP. The consolidated financial statements include the accounts of the Company and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The estimates reflected in the Company’s consolidated financial statements include, but are not limited to, certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, contingent assets and liabilities, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.

Revenue Recognition

The Company recognizes revenue when it transfers control of promised goods or services to its customers in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for those goods and services. See Note 3, “Revenue from Contracts with Customers” for further discussion on revenues.

Accounts Receivable, net

Accounts receivable consist of amounts billed and currently due from customers. The Company maintains an allowance for doubtful accounts for estimated losses. In determining the allowance, consideration includes the probability of recoverability based on past experience and general economic factors. Certain accounts receivable may be fully reserved when the Company becomes aware of any specific collection issues. The Company periodically reviews the aging of receivables, payment history and customer creditworthiness to determine if adjustments to the allowance for bad debt is necessary. Allowance for bad debt has been immaterial for all years presented.

Income Taxes

The Company accounts for income taxes using an asset and liability approach. Income tax (benefit) expense represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax bases of the Company’s assets and liabilities. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax attributes are expected to be recovered or paid, and are adjusted for changes in tax rates and tax laws when such changes are enacted.

The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more-likely-than-not to be realized. Valuation allowances are recorded to reduce deferred tax assets when it is more-likely-than-not that the future tax benefit will not be realized. The assessment of whether or not a valuation allowance is required involves weighing both positive and negative evidence, including both historical and prospective information, with greater weight given to evidence that is objectively verifiable. A history of recent losses is negative evidence that is difficult to overcome with positive evidence. In evaluating prospective information there are four sources of taxable income: reversals of taxable temporary differences, items that can be carried back to prior tax years (such as net operating losses), pre-tax income, and prudent and feasible tax planning strategies. Adjustments to the deferred tax valuation allowances are made in the period when those assessments are made.

The Company accounts for uncertain tax positions using a two-step recognition threshold and measurement analysis method to determine the financial statement impact of uncertain tax positions taken or expected to be taken in a tax return. Differences between tax positions taken in a tax return and amounts recognized in the financial statements are recorded as adjustments to other long-term assets and liabilities, or adjustments to deferred taxes, or both. The Company records the related interest and penalties to income tax (benefit) expense.

Net Income (Loss) per Common Share

The Company computes earnings per share using the two-class method. Basic earnings per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities as if those securities were converted or exercised. The Company’s potentially dilutive shares, which could include shares issuable upon conversion of the 2.625% Convertible Senior Notes due 2027 (the “Notes”), are considered to be common stock equivalents and are only included in the calculation of diluted net income per share when their effect is dilutive. The Company has the option to settle the Notes through cash settlement or a combination of cash and share settlement provided that the principal is settled in cash and the conversion spread is settled in cash or shares as elected by the Company. The Company applies the if-converted method for diluted earnings in order to reflect the conversion spread. During periods in which the Company incurs net losses, both basic and diluted loss per common share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.

Cash and Cash Equivalents

Cash and cash equivalents include savings deposits, certificates of deposit and money market funds that have original maturities of three months or less when purchased.

Restricted Cash

Restricted cash as of December 31, 2022 and 2021, represents primarily collateral for a letter of credit securing a lease obligation and a security deposit. The Company believes the carrying value of these assets approximates fair value.

Concentration of Risks and Limited Suppliers

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of trade accounts receivable. The Company periodically reviews its accounts receivable for collectability and provides for an allowance for doubtful accounts to the extent that amounts are not expected to be collected. The Company sells primarily to hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, and group practices.

As of December 31, 2022 and 2021, no customer accounted for greater than 10% of accounts receivable, net. No customer accounted for greater than 10% of revenues for the years ended December 31, 2022, 2021 and 2020.

The Company relies on certain materials used in its development and manufacturing processes, some of which are procured from only one or a few sources. The failure of one of these suppliers to deliver on schedule could delay or interrupt the manufacturing or commercialization process and would adversely affect the Company’s operating results. In addition, a disruption in the commercial supply of, or a significant increase in the cost of one of the Company’s materials from these sources could have a material adverse effect on the Company’s business, financial position and results of operations.

The Company currently relies on JHS as its significant manufacturer of DEFINITY and its sole source manufacturer of NEUROLITE, CARDIOLITE and evacuation vials for TechneLite. The Company has Mo-99 supply agreements with IRE of Belgium, running through December 31, 2023, with auto-renewal provisions and terminable upon notice of non-renewal, and with NTP and its subcontractor ANSTO, running through December 31, 2024.

The following table sets forth revenues for each of the Company’s products representing 10% or more of revenues:


	Year Ended December 31,
	2022		2021		2020
PYLARIFY	56.4	%	10.2	%	—	%
DEFINITY	26.2	%	54.7	%	62.8	%
TechneLite	9.5	%	21.5	%	25.4	%

Inventory

Inventory includes material, direct labor and related manufacturing overhead and is stated at the lower of cost and net realizable value on a first-in, first-out basis. The Company records inventory when the Company takes title to the product.

Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed as incurred. As of December 31, 2021, the Company had $6.1 million of such product costs included in inventories related to DEFINITY that had been manufactured through the Company’s in-house manufacturing capabilities. The Company received regulatory approval for the manufacture of DEFINITY at its new in-house manufacturing facility during the first quarter of 2022 and had no inventory pending regulatory approval as of December 31, 2022.

Property, Plant and Equipment, net

Property, plant & equipment are stated at cost. Replacements of major units of property are capitalized, and replaced properties are retired. Replacements of minor components of property and repair and maintenance costs are charged to expense as incurred. Certain costs to obtain or develop computer software are capitalized and amortized over the estimated useful life of the software. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets and recorded throughout costs of goods sold and operating expenses in the associated functional expense category which utilizes the associated asset. The estimated useful lives of the major classes of depreciable assets are as follows:


Class						Range of Estimated Useful Lives
Buildings						10 - 50 years
Land improvements						15 - 40 years
Machinery and equipment						3 - 15 years
Furniture and fixtures						15 years
Leasehold improvements						Lesser of lease term or 15 years
Computer software						3 - 5 years

Upon retirement or other disposal of property, plant & equipment, the cost and related amount of accumulated depreciation are removed from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds is included in operating income.

Included within machinery, equipment and fixtures are spare parts. Spare parts include replacement parts relating to plant & equipment and are either recognized as an expense when consumed or reclassified and capitalized as part of the related asset and depreciated over the remaining useful life of the related asset.

Business Combinations

The Company accounts for business combinations using the acquisition method of accounting. The Company recognizes the assets acquired and liabilities assumed in business combinations on the basis of their fair values at the date of acquisition. The Company assesses the fair value of assets acquired, including intangible assets, and liabilities assumed using a variety of methods. Each asset acquired and liability assumed is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of intangible assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant’s use of the asset and the appropriate discount rates. Acquired in-process research and development (“IPR&D”) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. Any excess purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. Transaction costs and restructuring costs associated with a business combination are expensed as incurred.

During the measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, all adjustments are recorded in the consolidated statements of operations as operating expenses or income. The Company recorded a measurement period adjustment of $2.6 million related to deferred taxes for the three months ended March 31, 2021, which finalized all measurement period adjustments related to the Progenics Acquisition.

Goodwill

Goodwill is not amortized but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely-than-not that they may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year.

In performing the Company’s annual assessment, the Company is permitted to first perform a qualitative test and if necessary, perform a quantitative test. If the Company is required to perform the quantitative impairment test of goodwill, the Company compares the fair value of a reporting unit to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company would record an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company estimates the fair value of its reporting units using discounted cash flow or other valuation models, such as comparative transactions and market multiples. The Company did not recognize any goodwill impairment charges during the years ended December 31, 2022, 2021 or 2020.

Intangible and Long-Lived Assets

The Company tests intangible and long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. The Company measures the recoverability of assets to be held and used by comparing the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If those assets are considered to be impaired, the impairment equals the amount by which the carrying amount of the assets exceeds the fair value of the assets. Any impairments are recorded as permanent reductions in the carrying amount of the assets. See Note 7, “Property, Plant and Equipment, Net” for further details on impairment. Long-lived assets, other than goodwill and other intangible assets that are held for sale are recorded at the lower of the carrying value or the fair market value less the estimated cost to sell.

Intangible assets, consisting of patents, trademarks, customer relationships, a currently marketed product, licenses and developed technology related to the Company’s products are amortized in a method equivalent to the estimated utilization of the economic benefit of the asset.

Costs of IPR&D intangible assets acquired as part of an asset acquisition that have no alternative future use are expensed when incurred. Milestone payments made after regulatory approval are capitalized as an intangible asset and amortized over an estimated useful life of the product. Cash payments related to acquired IPR&D intangible assets are reflected as an investing cash flow in the Company's consolidated statement of cash flows.

The Company’s IPR&D intangible assets includes intangible assets acquired in a business combination that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. Because obtaining regulatory approval can include significant risks and uncertainties, the eventual realized value of the acquired IPR&D projects may vary from their fair value at the date of acquisition. The Company classifies IPR&D intangible assets acquired in a business combination as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, the Company will determine the useful life and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, the Company writes-off the remaining carrying amount of the associated IPR&D intangible asset. IPR&D intangible assets are tested at least annually as of October 31 or when a triggering event occurs that could indicate a potential impairment and any impairment loss is recognized in the Company’s consolidated statements of operations. See Note 11, “Intangibles, net and Goodwill” for further details on impairment.

Contingencies

In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, product and environmental liability. The Company records accruals for those loss contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. The Company does not recognize gain contingencies until realized.

Convertible Notes

Effective as of January 1, 2021, the Company early adopted the provisions of ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. Upon adoption, the Company determined there was no impact for the year ended December 31, 2021. The provisions of ASU 2020-06 became applicable for the year ended December 31, 2022 in connection with the issuance of the Notes. This ASU provides guidance to simplify the complexity associated with accounting for convertible instruments and derivatives. For convertible instruments, the number of major separation models required were reduced. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for

embedded conversion features. The Company evaluates convertible notes to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. The change in fair value of any separately recognized derivative is recorded in the consolidated statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation.

Fair Values of Financial Instruments

The estimated fair values of the Company’s financial instruments, including its cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate the carrying values of these instruments due to their short term nature. The Company’s long-term debt has triggering events that would impact the fair value of the instruments. The Company determined that no triggering event has occurred during the year ended December 31, 2022. Since no triggering events have occurred, the estimated fair value of the Company’s long term debt approximates its carrying values. The fair value See Note 4, “Fair Value of Financial Instruments”.

Contingent Consideration Liabilities

The estimated fair value of contingent consideration liabilities, initially measured and recorded on the acquisition date, are considered to be a Level 3 instrument and are reviewed quarterly, or whenever events or circumstances occur that indicate a change in fair value. The contingent consideration liabilities are recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in general and administrative expenses in the consolidated statements of operations.

The estimated fair value is determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that include significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.

Significant changes in any of the probabilities of success would result in a significantly higher or lower fair value measurement. Significant changes in the probabilities as to the periods in which milestones will be achieved would result in a significantly lower or higher fair value measurement.

Derivative Instruments

The Company has used interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. To qualify for hedge accounting, the hedging instrument must be highly effective at reducing the risk from the exposure being hedged. Further, the Company must formally document the hedging relationship at inception and, on at least a quarterly basis, continually reevaluate the relationship to ensure it remains highly effective throughout the life of the hedge. The Company does not enter into derivative financial instruments for speculative or trading purposes.

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred. During the years ended December 31, 2022, 2021 and 2020, the Company incurred $26.0 million, $17.5 million and $5.2 million, respectively in advertising and promotion costs, which are included in sales and marketing in the consolidated statements of operations.

Research and Development

Research and development costs are expensed as incurred and relate primarily to the development of new products to add to the Company’s portfolio and costs related to its medical affairs and medical information functions. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and recognized as an expense as the goods are delivered or the related services are performed.

Foreign Currency

The consolidated statements of operations of the Company’s foreign subsidiaries are translated into U.S. Dollars using weighted-average exchange rates. The net assets of the Company’s foreign subsidiaries are translated into U.S. Dollars using the end of period exchange rates. The impact from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in accumulated other comprehensive loss in the consolidated balance sheets.

Remeasurement of the Company’s foreign currency denominated transactions are included in net income. Transaction gains and losses are reported as a component of other loss (income) in the consolidated statements of operations.

Stock-Based Compensation

The Company’s stock-based compensation cost is measured at the grant date of the stock-based award based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period, and includes an estimate of the awards that will be forfeited. The Company estimates the fair value of each stock-based award on its measurement date using either the current market price of the stock, the Black-Scholes option valuation model or the Monte Carlo simulation valuation model, whichever is most appropriate. The Black-Scholes and Monte Carlo simulation valuation models incorporate assumptions such as stock price volatility, the expected life of options or awards, a risk-free interest rate and dividend yield.

Expected volatility is based on the historical volatility of the Company’s stock price. The risk-free interest rates are based on quoted U.S. Treasury rates for securities with maturities approximating the awards’ expected lives. Expected lives are principally based on the Company’s historical exercise experience with previously issued awards. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.

Expense for performance restricted stock awards is recognized based upon the fair value of the awards on the date of grant and the number of shares expected to vest based on the terms of the underlying award agreement and the requisite service period(s).

Other Loss (Income)

Other loss (income) consisted of the following:


	Year Ended December 31,
(in thousands)	2022		2021		2020
Foreign currency losses (gains)	$	256	$	274	$	260
Tax indemnification expense (income), net	9,554		7,121		(2,218)
Interest income	(2,613)		(45)		(238)
Interest rate swap termination	(5,494)		—		—
Other	—		—		(2)
Total other loss (income)	$	1,703	$	7,350	$	(2,198)

Comprehensive Income (Loss)

Comprehensive income (loss) consists of net income (loss) and other gains and losses affecting stockholders’ equity that, under U.S. GAAP, are excluded from net income. For the Company, other comprehensive income (loss) consists of foreign currency translation gains and losses as well as realized and unrealized gains and losses on cash flow hedges related to the Company’s interest rate swaps. The accumulated other comprehensive income (loss) balance consists entirely of foreign currency translation gains and losses and realized and unrealized gains and losses on outstanding cash flow hedges related to the Company’s interest rate swaps.

Asset Retirement Obligations

The Company’s compliance with federal, state, local and foreign environmental laws and regulations may require it to remove or mitigate the effects of the disposal or release of chemical substances in jurisdictions where it does business or maintains properties. The Company establishes accruals when those costs are legally obligated and can be reasonably estimated. Accrual amounts are estimated, which may include the assistance of third party environmental specialists, and are based on currently available information, regulatory requirements, remediation strategies, historical experience, the relative shares of the total remediation costs, a relevant discount rate, and the time periods of when estimated costs can be reasonably predicted. Changes in these assumptions could impact the Company’s future reported results.

The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts campus. The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The fair value of a liability for asset retirement obligations is recognized in the period in which the liability is incurred. The liability is measured at the present value of the obligation expected to be incurred and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying values of the related long-lived assets and depreciated over the assets’ useful lives.

The Company has identified conditional asset retirement obligations related to the future removal and disposal of asbestos contained in certain of the buildings located on the Company’s North Billerica, Massachusetts campus. The Company believes the asbestos is appropriately contained and it is compliant with all applicable environmental regulations. If these properties undergo major renovations or are demolished, certain environmental regulations are in place, which specify the manner in which asbestos must be handled and disposed. The Company is required to record the fair value of these conditional liabilities if they can be reasonably estimated. As of December 31, 2022 and 2021, sufficient information was not available to estimate a liability for such conditional asset retirement obligations as the obligations to remove the asbestos from these properties have indeterminable settlement dates. As such, no liability for conditional asset retirement obligations has been recorded in the accompanying consolidated balance sheets as of December 31, 2022 and 2021.

Self-Insurance Reserves

The Company’s consolidated balance sheets at December 31, 2022 and 2021 include $0.9 million and $0.7 million of accrued liabilities associated with employee medical costs that are retained by the Company, respectively. The Company estimates the required liability of those claims on an undiscounted basis based upon various assumptions which include, but are not limited to, the Company’s historical loss experience and projected loss development factors. The required liability is also subject to adjustment in the future based upon changes in claims experience, including changes in the number of incidents (frequency) and change in the ultimate cost per incident (severity).

Recent Accounting Pronouncements

The Company has not adopted any new accounting standards during the year ended December 31, 2022.

Revenue from Contracts with Customers

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customers

Revenue from Contracts with Customers

Revenue Recognition

Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services. To achieve this core principle, the Company applies the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the Company satisfies a performance obligation.

Disaggregation of Revenue

The following table summarizes revenue by revenue source as follows:


	Year Ended December 31,
Major Products/Service Lines (in thousands)	2022		2021		2020
Product revenue, net(1)	$	887,038	$	400,356	$	327,695
License and royalty revenues(2)	48,023		24,852		11,715
Total revenues	$	935,061	$	425,208	$	339,410

______________________________

(1)The Company’s principal products include PYLARIFY, DEFINITY, and TechneLite and are categorized within product revenue, net. The Company applies the same revenue recognition policies and judgments for all of its principal products.

(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG.

The Company classifies its revenues into three product categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostics includes DEFINITY, TechneLite and other diagnostic imaging products. Radiopharmaceutical Oncology consists primarily of PYLARIFY and AZEDRA. Strategic Partnerships and Other Revenue includes strategic partnerships and other arrangements related to other products of the Company, such as royalty revenue from our license of RELISTOR.

On January 31, 2022, the Company entered into a global settlement agreement with Novartis Pharma AG (“Novartis”), Advanced Accelerator Applications USA, Inc. (“AAA”), Endocyte, Inc. (“Endocyte”) and their affiliates (the “Novartis Agreement”) to settle certain disputes between the parties. Under the Novartis Agreement, Novartis agreed to make a lump sum payment to the Company, as well as to reimburse the Company for certain fees and expenses in connection with certain German litigation, and the Company agreed to license certain intellectual property to Novartis. In addition, the Company agreed to supply PYLARIFY for clinical purposes at an arms-length value which will be recorded revenue in the future as product is provided. In accordance with the Company's ASC 606, Revenue from Contracts with Customers, assessment, Novartis is considered to be a customer. The Company determined that the $24.0 million constituted a single element which was satisfied on the date of the execution of the Novartis Agreement. The Company determined that the license of intellectual property carried a fair value of $24.0 million. As such, the Company assigned the value to the fair value of the license, which constitutes the entire transaction price and does not require further allocation. The Company determined that the $24.0 million represented the point at which the licensee was able to use and benefit from the license and recognized revenue when the license was granted to Novartis upon execution of the Novartis Agreement. The Company recognized the $24.0 million fee as revenue on its consolidated statement of operations for the quarter ended March 31, 2022. The Company received the $24.0 million payment in April 2022.

Revenue by product category on a net basis is as follows:


	Year Ended December 31,
(in thousands)	2022		2021		2020
DEFINITY	$	244,993	$	232,759	$	195,865
TechneLite	88,864		91,293		84,945
Other precision diagnostics	22,825		26,973		36,824
Total precision diagnostics	356,682		351,025		317,634
PYLARIFY	527,405		43,414		—
Other radiopharmaceutical oncology	4,102		5,473		10,022
Total radiopharmaceutical oncology	531,507		48,887		10,022
Strategic Partnerships and other revenue	46,872		25,296		11,754
Total revenues	$	935,061	$	425,208	$	339,410

Product Revenue, Net

The Company sells its products principally to hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, and group practices. The Company considers customer purchase orders, which in some cases are governed by master sales or group purchasing organization agreements, to be the contracts with a customer.

For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. In determining the transaction price, the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which the Company expects to be entitled.

The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 60 days from invoicing, the Company has elected to use the significant financing component practical expedient.

The Company allocates the transaction price to each distinct product based on their relative standalone selling price. The product price as specified on the purchase order is considered the standalone selling price as it is an observable input which depicts the price as if sold to a similar customer in similar circumstances.

Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which typically occurs upon delivery to the customer. Further, in determining whether control has transferred, the Company considers if there is a present right to payment and legal title, along with risks and rewards of ownership having transferred to the customer.

Frequently, the Company receives orders for products to be delivered over multiple dates that may extend across several reporting periods. The Company invoices for each delivery upon shipment and recognizes revenues for each distinct product delivered, assuming transfer of control has occurred.

The Company generally does not separately charge customers for shipping and handling costs, but any shipping and handling costs charged to customers are included in product revenue, net. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.

Variable Consideration

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the

Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect product revenue and earnings in the period such variances become known.

Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying consolidated balance sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations. The Company estimates the amount of rebates and allowances that are explicitly stated in the Company’s contracts based on a combination of actual purchases and an estimate of the customer’s buying patterns.

Product Returns: The Company generally offers customers a limited right of return due to non-conforming product. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. Reserves for product returns are not significant to the Company due to the nature of its products including radiopharmaceutical products with limited half-lives.

An analysis of the amount of, and change in, reserves is summarized as follows:


(in thousands)	Rebates and Allowances
Balance, January 1, 2021	$	9,350
Provision related to current period revenues	25,772
Adjustments relating to prior period revenues	14
Payments or credits made during the period	(24,159)
Balance, December 31, 2021	10,977
Provision related to current period revenues	26,683
Adjustments relating to prior period revenues	70
Payments or credits made during the period	(24,331)
Balance, December 31, 2022	$	13,399

License and Royalty Revenues

The Company has entered into licensing agreements, under which it licenses certain rights to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. The Company also has distribution licenses which are treated as combined performance obligations with the delivery of its products and are classified as product revenue, net.

In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the five-step approach stated earlier. The Company uses judgment in determining the number of performance obligations in a license agreement by assessing whether the license is distinct or should be combined with another performance obligation, as well as the nature of the license. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success.

Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Milestone Payments: At the inception of each arrangement that includes development or sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are outside the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license and royalty revenues and earnings in the period of adjustment. At December 31, 2022, the Company is constraining variable consideration related to development milestone payments requiring regulatory approvals and sales milestone payments related to achievement of certain sales targets.

Royalty Revenues: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

Contract Costs

The Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient to expense the costs as they are incurred, within sales and marketing expenses, since the amortization period is less than one year.

The Company recognized certain revenues as follows:


	Year Ended December 31,
(in thousands)	2022		2021
Amounts included in the contract liability at the beginning of the period	$	244	$	33

The Company did not record any revenue related to performance obligations satisfied (or partially satisfied) in previous periods during the years ended December 31, 2022 and 2021.

The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

•Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

•Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

•Level 3 — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.

The Company’s financial assets and liabilities measured at fair value on a recurring basis consist of money market funds, interest rate swaps, a contingent receivable and contingent consideration liabilities. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the consolidated balance sheets at fair value using quoted prices in active markets for identical assets. The fair value of the interest rate swaps is determined based on observable market-based inputs, including interest rate curves and reflects the contractual terms of these instruments, including the period to maturity. Please refer to Note 14, “Derivative Instruments”, for further details on the interest rate swaps. The Company recorded a contingent receivable and the contingent consideration liabilities resulting from the Progenics Acquisition at fair value based on inputs that are not observable in the market. Please refer to Note 8, “Business Combinations”, for further details on the acquisition.

The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:


	December 31, 2022
(in thousands)	Total Fair Value		Level 1		Level 2		Level 3
Assets:
Money market	$	342,646	$	342,646	$	—	$	—


Total assets	$	342,646	$	342,646	$	—	$	—
Liabilities:

Contingent consideration liabilities	$	111,600	$	—	$	—	$	111,600
Total liabilities	$	111,600	$	—	$	—	$	111,600


	December 31, 2021
(in thousands)	Total Fair Value		Level 1		Level 2		Level 3
Assets:
Money market	$	40,140	$	40,140	$	—	$	—
Interest rate swaps	357		—		357		—
Contingent receivable	9,300		—		—		9,300
Total assets	$	49,797	$	40,140	$	357	$	9,300
Liabilities:

Contingent consideration liabilities	86,200		—		—		86,200
Total liabilities	$	86,200	$	—	$	—	$	86,200

During the years ended December 31, 2022 and 2021, there were no transfers into or out of Level 3. On December 2, 2022, the Company voluntarily terminated the interest rate swap contracts in connection with the refinancing of debt.

As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics from CytoDyn Inc. (“CytoDyn”) related to a prior sale of certain intellectual property. The Company has the right to receive $5.0 million upon regulatory approval and a 5% royalty on net sales of approved products. The Company considers the contingent receivable a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows that included significant estimates and assumptions pertaining to regulatory events and sales targets. During the fourth quarter of 2022, the Company reduced the probability to zero as CytoDyn withdrew their regulatory application. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success.

As part of the Progenics Acquisition, the Company issued CVRs and recorded the fair value as part of consideration transferred. Each CVR will entitle its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively, subject to a maximum cap. Refer to Note 1, “Description of Business” for further details on the CVRs. The Company considers the contingent consideration liabilities relating to the CVRs a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value of these had been determined based on Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. Based on the U.S. net sales generated by PYLARIFY in 2022, the Company currently expects to pay out the full amount of the CVRs from available cash in the first half of 2023.

The Company also assumed contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013 (“2013 Acquisition”). These contingent consideration liabilities include potential payments of up to $70.0 million if the Company attains certain net sales targets primarily for AZEDRA and 1095 and a $5.0 million 1095 commercialization milestone. Additionally, there is a potential payment of up to $10.0 million related to a 1404 commercialization milestone. The Company’s total potential payments related to the 2013 Acquisition are approximately $85.0 million. The Company considers the contingent consideration liabilities relating to the 2013 Acquisition each a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value of these was determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs with respect to 1095 and 1404 are the probabilities of achieving regulatory approval of those development projects and subsequent commercial success.

Significant changes in any of the probabilities of success, the probabilities as to the periods in which sales targets and milestones will be achieved, discount rates or underlying revenue forecasts would result in a significantly higher or lower fair value measurement. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the consolidated statements of operations. The Company can give no assurance that the actual amounts paid, if any, in connection with the contingent consideration liabilities, including the CVRs, will be consistent with any recurring fair value estimate of such contingent consideration liabilities.

The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs as of December 31, 2022.


	Fair Value as of						Assumptions
(in thousands)	December 31, 2022		December 31, 2021		Valuation Technique	Unobservable Input	December 31, 2022	December 31, 2021
Contingent receivable:
Regulatory milestone	$	—	$	2,500	Probability adjusted discounted cash flow model	Period of expected milestone achievement	N/A	2022
						Probability of success	0%	70	%
						Discount rate	N/A	17	%
Royalties	—		6,800		Probability adjusted discounted cash flow model
						Probability of success	0%	10% - 60%
						Discount rate	N/A	17	%
Total	$	—	$	9,300


	Fair Value as of						Assumptions
(in thousands)	December 31, 2022		December 31, 2021		Valuation Technique	Unobservable Input	December 31, 2022		December 31, 2021
Contingent consideration liability:
Net sales targets - PYLARIFY (CVRs)	$	99,700	$	73,200	Probability adjusted discounted cash flow model (as of 12/31/2022) Monte Carlo simulation (as of 12/31/2021)	Period of expected milestone achievement and sales targets	2022 - 2023		2022 - 2023
						Probability of success	100	%	N/A
						Discount rate	N/A		17	%
1095 commercialization milestone	1,700		1,900		Probability adjusted discounted cash flow model
						Period of expected milestone achievement	2026		2026
						Probability of success	40	%	40	%
						Discount rate	3.8	%	1.3	%



Net sales targets - AZEDRA and 1095	10,200		11,100		Monte Carlo simulation
						Probability of success and sales targets	20% - 100%		40% - 100%
						Discount rate	16% - 17%		16% - 17%
Total	$	111,600	$	86,200

For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:


	Financial Assets				Financial Liabilities
(in thousands)	Years Ended December 31,				Years Ended December 31,
	2022		2021		2022		2021
Fair value, beginning of period	$	9,300	$	11,300	$	86,200	$	15,800

Changes in fair value included in net income (loss)	(9,300)		(2,000)		25,400		70,400

Fair value, end of period	$	—	$	9,300	$	111,600	$	86,200

The change in fair value of the contingent financial asset and contingent financial liabilities, including the CVRs, resulted in a general and administrative expense of $34.7 million for the year ended December 31, 2022 and was primarily due to changes in revenue forecasts, changes in market conditions, an increase in discount rates (excluding the CVRs) and the passage of time. The Company expects to make all applicable cash payments related to the CVRs in the first half of 2023. As of December 31, 2022, the Company had $99.7 million in current liabilities to account for the expected payments related to the CVRs.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Income Taxes

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Income Taxes

The components of income (loss) before provision (benefit) for income taxes consists of the following:


	Year Ended December 31,
(in thousands)	2022		2021		2020
U.S.	$	29,012	$	(76,389)	$	(5,495)
International	(2,293)		1,351		(5,984)
Income (loss) before income taxes	$	26,719	$	(75,038)	$	(11,479)

The Company’s provision (benefit) for income taxes consists of the following:


	Year Ended December 31,
(in thousands)	2022		2021		2020
Current
Federal	$	42,532	$	—	$	—
State	4,302		(8,166)		3,158
International	(166)		(30)		170
	46,668		(8,196)		3,328
Deferred
Federal	(39,920)		1,048		(1,506)
State	(8,315)		3,058		(178)
International	219		331		350
	(48,016)		4,437		(1,334)
Income tax (benefit) expense	$	(1,348)	$	(3,759)	$	1,994

The reconciliation of income taxes at the U.S. federal statutory rate to the income tax (benefit) expense is as follows:


	Year Ended December 31,
(in thousands)	2022		2021		2020
U.S. statutory rate	$	5,611	$	(15,758)	$	(2,411)
Permanent items	2,309		1,764		1,176
Acquisition costs - Progenics	—		—		2,723
Recognition of deferred tax asset - assets held for sale	—		—		(3,000)
Section 162(m)	247		1,028		717
Uncertain tax positions	(12,629)		(8,952)		2,818
Other tax credits	(4,085)		(990)		(1,065)
State and local taxes	67		656		1,457
Impact on deferred taxes of change in tax rate	4,169		3,049		—
Non-deductible changes in fair value of contingent assets and liabilities	5,422		15,015		230
Foreign tax rate differential	68		23		(254)
Valuation allowance	(30)		(400)		(318)
Benefit of windfall related to stock compensation	(4,612)		(1,164)		(128)
Change in indemnification deferred tax asset	2,343		1,786		(590)
Other	(228)		184		639
Income tax (benefit) expense	$	(1,348)	$	(3,759)	$	1,994

The components of deferred income tax assets (liabilities) are as follows:


	December 31,
(in thousands)	2022		2021
Deferred Tax Assets
Federal benefit of state tax liabilities	$	1,739	$	4,292
Reserves, accruals and other	31,532		27,159
Inventory obsolescence	919		297
Capitalized research and development	79,946		768
Amortization of intangibles other than goodwill	—		502
Net operating loss carryforwards	88,014		122,944
Depreciation	—		1,102
Deferred tax assets	202,150		157,064
Deferred Tax Liabilities
Reserves, accruals and other	(5,354)		(3,026)
Intangible assets	(80,770)		(87,351)
Amortization of intangibles other than goodwill	(385)		—
Depreciation	(1,469)		—
Deferred tax liability	(87,978)		(90,377)
Less: valuation allowance	(3,525)		(3,923)
	$	110,647	$	62,764
Recorded in the accompanying consolidated balance sheets as:
Noncurrent deferred tax assets, net	$	110,647	$	62,764

The Tax Cuts and Jobs Act (the “Act”) was enacted on December 22, 2017. Under the Act, research and experimental expenditures incurred for tax years beginning after December 31, 2021, must be capitalized and amortized ratably over five or fifteen years for tax purposes, depending on where the research activities are conducted. If the requirement to capitalize Section 174 expenditures is not modified, it may also impact our effective tax rate and our cash tax liability in future years.The increase in worldwide net deferred tax asset is primarily due to the tax capitalization of the Company’s current year research and development expenses that are not currently deductible in 2022, offset by utilization of a portion of its net operating losses.

The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more-likely-than-not realizable, the Company evaluated all available positive and negative evidence. As of December 31, 2022 and 2021, the Company maintains a valuation allowance of $3.5 million and $3.9 million, respectively, related to net deferred tax assets of certain of its foreign subsidiaries and U.S. acquired tax credits.

Utilization of net operating loss carryforwards and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that could occur in the future in accordance with Section 382 of the Internal Revenue Code of 1986 (“IRC Section 382”) and with Section 383 of the Internal Revenue Code of 1986, as well as similar state provisions. These ownership changes may limit the amount of net operating loss carryforwards and research and development credit carryforwards that can be utilized annually to offset future taxable income and taxes, respectively. In general, an ownership change, as defined by IRC Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period.

At December 31, 2022, the Company had U.S. federal net operating loss carryforwards of approximately $338.4 million, $200.4 million of which will expire between 2024 and 2037, and $138.0 million of which can be carried forward indefinitely. The Company’s state net operating losses are $11.6 million on a tax-effected basis, which will expire between 2024 and 2040. The Company has state research credit carryforwards of $2.9 million, which will expire between 2024 and 2037. The Company has state investment tax credit carryforwards of $1.4 million net of federal impact which have no expiration date.

The Company’s U.S. federal income tax returns are subject to examination for three years after the filing date of the return. The state and foreign income tax returns are subject to examination for periods varying from three to four years after filing, depending on the specific jurisdictions’ statutes of limitation, and in the case of Sweden, up to six years after the end of the financial year.

A reconciliation of the Company’s changes in uncertain tax positions for 2022 and 2021 is as follows:


(in thousands)	Amount
Balance of uncertain tax positions as of January 1, 2021	$	5,292
Additions related to current year tax positions	—
Reductions related to prior year tax positions	(188)
Settlements	(1,446)
Lapse of statute of limitations	—
Balance of uncertain tax positions as of December 31, 2021	3,658
Additions related to current year tax positions	—
Reductions related to prior year tax positions	(1,180)
Settlements	(306)
Lapse of statute of limitations	(692)
Balance of uncertain tax positions as of December 31, 2022	$	1,480

In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb (“BMS”) in 2008, the Company recorded a liability for uncertain tax positions related to the acquired business and simultaneously entered into an agreement to indemnify with BMS for any payments made to settle those uncertain tax positions with the taxing authorities. A long-term receivable is recorded within other long-term assets to account for the expected value to the Company of future indemnification payments, net of actual tax benefits received, to be paid on behalf of the Company by BMS.

In accordance with the Company’s accounting policy, the change in the tax liability, penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within income tax expense. As these reserves change, adjustments are included in income tax expense while the offsetting adjustment is included in other income. Assuming that the receivable from BMS continues to be considered recoverable by the Company, there will be no effect on net income and no net cash outflows related to these liabilities.

As of December 31, 2022 and 2021, total liabilities for uncertain tax positions including interest and penalties were $8.3 million and $20.9 million, respectively, consisting of uncertain tax positions of $1.5 million and $3.7 million, respectively, interest accruals of $6.4 million and $16.5 million, respectively, and penalty accruals of $0.4 million and $0.8 million, respectively. As of December 31, 2022 and 2021, these liabilities were included in other long-term liabilities. Included in the 2022, 2021 and 2020 tax provisions are a benefit of $12.6 million, a benefit of $9.0 million and an expense of $2.8 million, respectively, relating to accrual of interest, net of benefits for reversals of uncertain tax positions recognized upon settlements, effective settlements, or lapses of relevant statutes of limitation.

The total long-term asset related to the indemnification was $3.9 million and $13.5 million at December 31, 2022 and 2021, respectively. Included in other (income) loss for the years ended December 31, 2022, 2021 and 2020, is tax indemnification expense (income), net of $9.6 million, $7.1 million and $(2.2) million, respectively.

On August 16, 2022, the “Inflation Reduction Act” (H.R. 5376) was signed into law in the United States. We do not currently expect the Inflation Reduction Act to have a material impact on our financial results.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Inventory

12 Months Ended

Dec. 31, 2022

Inventory Disclosure [Abstract]

Inventory

Inventory consisted of the following:


	December 31,
(in thousands)	2022		2021
Raw materials	$	19,987	$	15,505
Work in process	8,234		13,042
Finished goods	7,254		6,582
Total inventory	$	35,475	$	35,129

Inventory costs associated with products that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefit of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. As of December 31, 2021, the Company had $6.1 million of such product costs included in inventories related to DEFINITY that had been

manufactured through the Company’s in-house manufacturing capabilities. The Company received regulatory approval to manufacture DEFINITY at its new in-house manufacturing facility during the first quarter of 2022 and has no inventory pending regulatory approval as of December 31, 2022.

Property, Plant & Equipment, Net

12 Months Ended

Dec. 31, 2022

Property, Plant and Equipment [Abstract]

Property, Plant & Equipment, Net

Property, Plant and Equipment, Net

Property, plant and equipment, net, consisted of the following:


	December 31,
(in thousands)	2022		2021
Land	$	13,450	$	13,450
Buildings	76,329		73,559
Machinery, equipment and fixtures	92,604		83,608
Computer software	25,864		24,384
Construction in progress	14,047		10,686
	222,294		205,687
Less: accumulated depreciation and amortization	(100,128)		(88,915)
Total property, plant and equipment, net	$	122,166	$	116,772

Depreciation and amortization expense related to property, plant & equipment, net, was $13.7 million, $13.2 million and $12.5 million for the years ended December 31, 2022, 2021 and 2020, respectively.

The Company tests long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. During the year ended December 31, 2021, the Company reviewed certain facts relating to an asset group that included the right-of-use (“ROU”) asset associated with the lease of office space in the World Trade Center (the “WTC lease”) in New York City and resulted in a change to the asset group due to the negotiation of a sublease. Please refer to Note 17, “Leases” for further details.

Business Combinations

12 Months Ended

Dec. 31, 2022

Business Combination and Asset Acquisition [Abstract]

Business Combinations

On June 19, 2020, the Company completed the Progenics Acquisition. The acquisition combined the commercialization, supply chain and manufacturing expertise of the Company with the currently commercialized products and research and development pipeline of Progenics. Progenics brought to the Company several commercial products and a pipeline of product candidates that further diversify the Company’s commercial and clinical development portfolios.

Under the terms of the Merger Agreement, the Company acquired all the issued and outstanding shares of Progenics common stock for a purchase price of $419.0 million by means of an all-stock transaction, which includes options to purchase Holdings common stock (“Replacement Stock Options”) for precombination services as well as CVRs.

The CVRs were accounted for as contingent consideration, the fair value of which was determined using a Monte Carlo simulation. Additionally, the fair value of the Replacement Stock Options was recorded as a component of consideration transferred. Finally, as a result of the Progenics Acquisition, Lantheus effectively settled an existing bridge loan with Progenics at the recorded amount (principal and accrued interest) of $10.1 million, representing the effective settlement of a preexisting relationship. This effective settlement of the bridge loan was treated as a component of consideration transferred. The Company determined that the bridge loan was at market terms and no gain or loss was recorded upon settlement.

The acquisition date fair value of the consideration transferred in the acquisition consisted of the following:


(in thousands)	Amount
Issuance of common stock	$	398,110
Fair value of replacement stock options	7,125
Fair value of bridge loan settled at close	10,074
Fair value of contingent considerations (CVRs)	3,700
Total consideration transferred	$	419,009

The transaction was accounted for as a business combination which requires that assets acquired and liabilities assumed be recognized at their fair value as of the acquisition date. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed on the acquisition date, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company’s results of operations. The Company recorded a measurement period adjustment of $2.6 million related to deferred taxes for the three months ended March 31, 2021, which finalized all measurement period adjustments related to the Progenics Acquisition.

The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as measurement period adjustments made to the amounts initially recorded in June 2020. The measurement period adjustments primarily resulted from finalizing the fair values of certain intangible assets and liabilities, deferred taxes and other changes to certain tangible assets and liability accounts. Measurement period adjustments were recognized in the reporting period in which the adjustments were determined and calculated as if the accounting had been completed at the acquisition date. The related impact to net loss that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial to the consolidated financial statements.


(in thousands)	Amounts Recognized as of Acquisition Date (as previously reported)		Measurement Period Adjustments		Amounts Recognized as of Acquisition Date (as adjusted)
Cash and cash equivalents	$	15,421	$	—	$	15,421
Accounts receivable	5,787		—		5,787
Inventory	915		160		1,075
Other current assets	3,250		434		3,684
Property, plant and equipment	14,972		—		14,972
Identifiable intangible assets (weighted-average useful life):
Currently marketed product (15 years)	142,100		800		142,900
Licenses (11.5 years)	87,500		(1,700)		85,800
Developed technology (9 years)	3,000		(600)		2,400
IPR&D	150,900		200		151,100
Other long-term assets	37,631		—		37,631
Accounts payable	(1,616)		—		(1,616)
Accrued expenses and other liabilities	(8,207)		(80)		(8,287)
Other long-term liabilities	(30,778)		(380)		(31,158)
Long-term debt and other borrowings	(40,200)		—		(40,200)
Deferred tax liabilities	(3,717)		(2,258)		(5,975)
Goodwill	42,051		3,424		45,475
Total consideration transferred	$	419,009	$	—	$	419,009

Intangible assets acquired consist of currently marketed products, licenses, developed technology and in-process research and development (“IPR&D”). The fair value of the acquired intangible assets was determined based on estimated future revenues, royalty rates and discount rates, among other variables and estimates. The acquired intangible assets subject to amortization were assigned useful lives based on the expected use of the assets and the regulatory and economic environment within which they are being used and are being amortized on a straight-line basis over the respective estimated useful lives. The estimated fair values of the IPR&D assets were determined based on the present values of the expected cash flows to be generated by the respective underlying assets. The Company used a discount rate of 23.0% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics, related to a prior sale of certain intellectual property. The estimated fair value of the acquired contingent receivable of $10.1 million was determined by applying a probability adjusted discounted cash flow model based on estimated future expected payments and recorded in other long-term assets.

The goodwill recognized is attributable to future technologies that are not separately identifiable that could potentially add to the currently developed and pipeline products and Progenics’ assembled workforce. Future technologies did not meet the criteria for recognition separately from goodwill because they are part of the future development and growth of the business. Goodwill of $45.5 million recognized in connection with the acquisition is not deductible for tax purposes.

The Company recognized $11.9 million of acquisition-related costs, including legal, accounting, compensation arrangements and other related fees that were expensed when incurred in the year ended December 31, 2020, respectively. These costs are recorded in general and administrative expenses in the consolidated statements of operations.

Progenics Pro Forma Financial Information

Progenics has been included in the Company’s consolidated financial statements since the acquisition date. Progenics contributed revenues of $12.4 million, as well as a net loss of $27.1 million to the Company’s consolidated statement of operations for the year ended December 31, 2020.

The following unaudited pro forma financial information presents the Company’s results as if the Progenics Acquisition had occurred on January 1, 2019:


	Year Ended December 31, 2020
(in thousands)	Amount
Pro forma revenue	$	350,315
Pro forma net loss	$	29,190

The unaudited pro forma financial information for all periods presented adjusts for the effects of material business combination items, including amortization of acquired intangible assets, transaction-related costs, adjustments to interest expense related to the assumption of long-term debt, retention and severance bonuses and the corresponding income tax effects of each. These pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the operating results of the Company that would have been achieved had the Progenics Acquisition actually taken place on January 1, 2019. In addition, these results are not intended to be a projection of future results and do not reflect events that may occur after the Progenics Acquisition, including, but not limited to, revenue enhancements, cost savings or operating synergies that the combined company may achieve as a result of the Progenics Acquisition.

Sale of Puerto Rico Subsidiary

12 Months Ended

Dec. 31, 2022

Discontinued Operations and Disposal Groups [Abstract]

Sale of Puerto Rico Subsidiary

During the fourth quarter of 2020, the Company entered into a stock purchase agreement (the “SPA”) with one of its existing radiopharmacy customers to sell all the stock of its Puerto Rico radiopharmacy subsidiary. The assets were classified as held for sale and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2020. The transaction was consummated on January 29, 2021.

The purchase price for the stock sale was $18.0 million in cash, which included a holdback amount of $1.8 million that was remitted to the Company as of December 31, 2021, and paid in the first quarter of 2022; the purchase price also included a working capital adjustment. The SPA contained customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the SPA.

The Company determined that this sale of certain net assets did not constitute a strategic shift that had a major effect on the Company’s operations or financial results. As a result, this transaction was not classified as discontinued operations in the Company’s accompanying consolidated financial statements.

The following table summarizes the major classes of assets and liabilities sold as of January 29, 2021, the date of sale:



(in thousands)	January 29, 2021
Current Assets:
Cash and cash equivalents	$	540
Accounts receivable, net	1,959
Inventory	530
Other current assets	65
Total current assets	3,094
Non-Current Assets:
Property, plant & equipment, net	780
Intangibles, net	96
Other long-term assets	774
Total assets held for sale	$	4,744

Current Liabilities:
Accounts payable	$	185
Accrued expense and other liabilities	369
Total current liabilities	554
Non-Current Liabilities:
Asset retirement obligations	306
Other long-term liabilities	588
Total liabilities held for sale	$	1,448

The sale resulted in a pre-tax book gain of $15.3 million, which was recorded within operating income (loss) in the consolidated statements of operations for the year ended December 31, 2021.

Asset Retirement Obligations

12 Months Ended

Dec. 31, 2022

Asset Retirement Obligation Disclosure [Abstract]

Asset Retirement Obligations

The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts and Somerset, New Jersey sites. As of December 31, 2022, the liability is measured at the present value of the obligation expected to be incurred, of approximately $25.1 million.

The Company previously operated a production facility which manufactured and processed radioactive materials at its San Juan, Puerto Rico site. As of December 31, 2020, the liability for the San Juan, Puerto Rico site was recorded in liabilities held for sale and the sale was consummated on January 29, 2021.

The following table provides a summary of the changes in the Company’s asset retirement obligations:


(in thousands)	Amount
Balance, January 1, 2022	$	20,833
Change in useful life estimate	280
Accretion expense	1,430
Balance, December 31, 2022	$	22,543

In December 2021, the Company evaluated the accretion timeline of an asset group due to a revision in the planned period of use at the North Billerica site. As a result of the accelerated timeline, the Company determined the asset group’s present value exceeded the current value recorded as of December 31, 2021. The Company recorded a non-cash adjustment of $5.3 million in 2021 to anticipate a revision in the end of useful life by the end of 2022.

The Company is required to provide the Massachusetts Department of Public Health and New Jersey Department of Environmental Protection financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts and Somerset, New Jersey production facilities upon closure, although the Company has no current plans to close the facilities. The Company has provided this financial assurance in the form of a $30.3 million surety bond.

Intangibles, Net and Goodwill

12 Months Ended

Dec. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Intangibles, Net and Goodwill

Intangibles, net, consisted of the following:


	December 31, 2022
(in thousands)	Useful Lives (in years)	Amortization Method	Cost		Accumulated Amortization		Net
Trademarks	15 - 25	Straight-Line	$	13,540	$	(12,061)	$	1,479
Customer relationships	15 - 25	Accelerated	96,681		(95,009)		1,672
Currently marketed product	9 - 15	Straight-Line	275,700		(47,628)		228,072
Licenses	11 - 16	Straight-Line	85,800		(19,101)		66,699
Developed technology	9	Straight-Line	2,400		(677)		1,723
IPR&D	N/A	N/A	15,640		—		15,640
Total			$	489,761	$	(174,476)	$	315,285


	December 31, 2021
(in thousands)	Useful Lives (in years)	Amortization Method	Cost		Accumulated Amortization		Net
Trademarks	15 - 25	Straight-Line	$	13,540	$	(11,510)	$	2,030
Customer relationships	15 - 25	Accelerated	96,880		(94,630)		2,250
Currently marketed product	15	Straight-Line	275,700		(23,345)		252,355
Licenses	11 - 16	Straight-Line	85,800		(11,555)		74,245
Developed technology	9	Straight-Line	2,400		(410)		1,990
IPR&D	N/A	N/A	15,640		—		15,640
Total			$	489,960	$	(141,450)	$	348,510

The Company recorded amortization expense for its intangible assets of $33.2 million, $27.5 million and $10.8 million for the years ended December 31, 2022, 2021 and 2020, respectively.

In May 2021, PyL (18F-DCFPyL) was approved by the FDA under the name PYLARIFY. Accordingly, the Company reclassified the associated asset of $132.8 million from IPR&D to currently marketed products and commenced amortization of the asset.

The Company performed its annual impairment test of its IPR&D intangible assets as of October 31, 2020. As a result of a timing delay in the development of an AZEDRA IPR&D intangible asset due to the impact of COVID-19, the Company determined that the carrying value of $18.3 million exceeded the fair value of the asset. Accordingly, the Company recorded a non-cash impairment charge of $2.7 million for the year ended December 31, 2020 in research and development expenses in the consolidated statements of operations. The estimated fair value of the AZEDRA IPR&D intangible asset was determined based on the present values of the expected cash flows. The Company used a discount rate of 23.0% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:


(in thousands)	Amount
2023	$	32,638
2024	32,563
2025	32,508
2026	32,497
2027	32,482
2028 and thereafter	136,957
Total	$	299,645

Changes in the carrying amounts of goodwill for the years ended December 31, 2022 and 2021, were as follows:


	December 31,
(in thousands)	2022		2021
Balance, Beginning of year	$	61,189	$	58,632
Increase from acquisition	—		2,557
Balance, End of year	$	61,189	$	61,189

Accrued Expenses and Other Liabilities and Other Long-Term Liabilities

12 Months Ended

Dec. 31, 2022

Payables and Accruals [Abstract]

Accrued Expenses and Other Liabilities and Other Long-Term Liabilities

Accrued expenses and other liabilities and other long-term liabilities are comprised of the following:


	December 31,
(in thousands)	2022		2021
Compensation and benefits	$	30,425	$	22,730
Freight, distribution and operations	49,067		16,157
Accrued rebates, discounts and chargebacks	13,399		10,977
Accrued professional fees	8,668		2,850

Other	25,525		5,354
Total accrued expenses and other liabilities	$	127,084	$	58,068

Operating lease liabilities (Note 17)	$	25,442	$	16,546
Long-term contingent liability (Note 4)	11,900		86,200
Other long-term liabilities	8,813		22,148
Total other long-term liabilities	$	46,155	$	124,894

Long-Term Debt, Net, and Other Borrowings

12 Months Ended

Dec. 31, 2022

Debt Disclosure [Abstract]

Long-Term Debt, Net, and Other Borrowings

Long-Term Debt, Net, and Other BorrowingsAs of December 31, 2022, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:


(in thousands)	Amount
2023	$	—
2024	—
2025	—
2026	—
2027	575,000
Total principal outstanding	575,000

Unamortized debt issuance costs	(17,519)
Finance lease liabilities	585
Total	558,066
Less: current portion	(354)
Total long-term debt, net, and other borrowings	$	557,712

In December 2022, the Company refinanced its existing credit facility, consisting of (i) a $200.0 million five-year term loan facility (the “2019 Term Facility”) and (ii) a $200.0 million five-year revolving credit facility (the “2019 Revolving Facility” and, together with the 2019 Term Facility, the “2019 Facility”), with a new $100.0 million delayed draw term loan facility (the “2022 Term Facility” and, the loans thereunder, the “Term Loans”) and a new $350.0 million five-year revolving credit facility (the “2022 Revolving Facility” and, together with the 2022 Term Facility, the “2022 Facility”).

The Company used approximately $7.8 million of cash on hand to primarily repay the principal amount of the loans outstanding related to the 2019 Facility through the nine months ended September 30, 2022. In addition, in December 2022, the Company used approximately $167.6 million of cash on hand to repay in full the aggregate remaining principal amount of the loans outstanding under the 2019 Facility and to pay related interest, transaction fees and expenses.

The Company paid off the 2019 Term Facility using available cash and did not utilize another term loan to fund the payoff. While the 2022 Term Facility allowed for a delayed draw term loan, the loan was not drawn upon. The Company recorded a loss on extinguishment of debt of $0.6 million related to the write-off of unamortized debt issuance costs and debt discounts associated with the 2019 Term Facility. In addition, the Company incurred and capitalized $2.7 million of new deferred financing costs related to the refinancing.

2022 Term Facility

The Company expected to draw from the 2022 Term Facility only if a proposed offering of notes by the Company was not consummated. The commitment of the lenders to provide the 2022 Term Facility was terminated upon the completion of such note offering in December 2022. The 2022 Term Facility included a commitment fee equal to 0.20% per annum on the average daily unused amount of the 2022 Term Facility, which would have been payable commencing on January 16, 2023 and would have ended on the earliest of (i) the day the Term Loans under the 2022 Term Facility were funded, (ii) the last day of the delayed draw availability period and (iii) the day the commitments under the 2022 Term Facility were reduced to zero. The Company did not draw from the 2022 Term Facility and, as such, no interest is due under this instrument.

2022 Revolving Facility

Under the terms of the 2022 Revolving Facility, the lenders are committed to extending credit to the Company from time to time until December 2, 2027 consisting of revolving loans (the “Revolving Loans”) in an aggregate principal amount not to exceed $350.0 million (the “Revolving Commitment”) at any time, including a $20.0 million sub-facility for the issuance of letters of credit (the “Letters of Credit”) and a $10.0 million sub-facility for swingline loans (the “Swingline Loans”). The Letters of Credit, Swingline Loans and the Revolving Loans, if used, are expected to be used for working capital and for other general corporate purposes.

The Revolving Loans bear interest, with pricing based from time to time at the Company’s election, at (i) the secured overnight financing rate as published by the Federal Reserve Bank of New York on its website plus an applicable margin that ranges from 1.50% to 2.50% based on the Company’s total net leverage ratio or (ii) the alternative base rate plus an applicable margin that ranges from 0.50% to 1.50% based on the Company’s total net leverage ratio. The 2022 Revolving Facility also includes an unused commitment fee at a rate ranging from 0.15% to 0.35% per annum based on the Company’s total net leverage ratio.

The Company is permitted to voluntarily prepay the Revolving Loans, in whole or in part, or reduce or terminate the Revolving Commitment, in each case, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans, Letters of Credit and Swingline Loans exceeds the total Revolving Commitment, the Company must prepay the Revolving

Loans in an amount equal to such excess. The Company is not required to make mandatory prepayments under the 2022 Revolving Facility. As of December 31, 2022, there were no outstanding borrowings under the 2022 Revolving Facility.

The Company has the right to request an increase to the Revolving Commitment in an aggregate principal amount of up to the sum of $335.0 million or consolidated EBITDA for the four consecutive fiscal quarters most recently ended, plus additional amounts in certain circumstances (collectively, the “Incremental Cap”), minus certain incremental term loans made pursuant to specified incremental term loan commitments (“Incremental Term Loans”). The Company has the right to request Incremental Term Loans in an aggregate principal amount of up to the Incremental Cap less any incremental increases to the Revolving Commitment. Proceeds of Incremental Term Loans may be used for working capital and for other general corporate purposes and will bear interest at rates agreed between the Company and the lenders providing the Incremental Term Loans.

2022 Facility Covenants

The 2022 Facility contains a number of affirmative, negative and reporting covenants, as well as financial maintenance covenants pursuant to which the Company is required to be in quarterly compliance, measured on a trailing four quarter basis, with two financial covenants. The minimum interest coverage ratio, commencing with the fiscal quarter ended December 31, 2022, must be at least 3.00 to 1.00. The maximum total net leverage ratio permitted by the financial covenant is displayed in the table below:

2022 Credit Agreement


Period			Total Net Leverage Ratio
Q1 2023 to Q4 2023			4.00 to 1.00
Q1 2024 and thereafter			3.50 to 1.00

The 2022 Facility contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.

Upon an event of default, the Administrative Agent will have the right to declare the loans and other obligations outstanding under the 2022 Facility immediately due and payable and all commitments immediately terminated.

The 2022 Facility is guaranteed by Holdings, and certain subsidiaries of LMI, including Progenics and Lantheus MI Real Estate, LLC, and obligations under the 2022 Facility are generally secured by first priority liens over substantially all of the assets of each of LMI, Holdings, and certain subsidiaries of LMI, including Progenics and Lantheus MI Real Estate, LLC (subject to customary exclusions set forth in the transaction documents) owned as of December 2, 2022 or thereafter acquired.

Convertible Notes

On December 8, 2022, the Company issued $575.0 million in aggregate principal amount of 2.625% Convertible Senior Notes due 2027 (the “Notes”), which includes $75.0 million in aggregate principal amount of Notes sold pursuant to the full exercise of the initial purchasers’ option to purchase additional Notes. The Notes were issued under an indenture, dated as of December 8, 2022 (the “Indenture”), among the Company, LMI (the “Guarantor”), a wholly owned subsidiary of the Company, as Guarantor, and U.S. Bank Trust Company, National Association, as Trustee. The net proceeds from the issuance of the Notes were approximately $557.8 million after deducting the initial purchasers’ discounts and offering expenses payable by the Company.

The Notes are senior unsecured obligations of the Company. The Notes are fully and unconditionally guaranteed on a senior unsecured basis by the Guarantor. The Notes bear interest at a rate of 2.625% per year, payable semi-annually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023, and will mature on December 15, 2027 unless earlier redeemed, repurchased or converted in accordance with their terms. The initial conversion rate for the Notes is 12.5291 shares of the Company’s common stock per $1,000 in principal amount of Notes (which is equivalent to an initial conversion price of approximately $79.81 per share of the Company’s common stock, representing an initial conversion premium of approximately 42.5% above the closing price of $56.01 per share of the Company’s common stock on December 5, 2022). In no event shall the conversation rate per $1,000 in principal amount of notes exceed 17.8539 shares of the Company’s common stock. Prior to the close of business on the business day immediately preceding September 15, 2027, the Notes may be converted at the option of the holders only upon occurrence of specified events and during certain periods, and thereafter until the close of business on the business day immediately preceding the maturity date, the Notes may be converted at any time. The Company will satisfy any conversion by paying cash up to the aggregate principal amount of the Notes to be converted and by paying or delivering, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at its election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the Notes being converted. The Company may redeem for cash all or any

portion of the Notes, at its option, on or after December 22, 2025 if the closing sale price per share of the Company’s common stock exceeds 130% of the conversion price of the Notes for a specified period of time. The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

The Company evaluated the Notes upon completion of the sale and concluded on the following features:

•Conversion Feature: The Company determined that the conversion feature qualifies for the classification of equity. As a result, the conversion feature should not be bifurcated as a derivative instrument and the Notes were accounted for as a single liability.

•Redemption Features: The redemption features were reviewed within the Notes and the Company determined that the redemption features are closely related to the Notes and as such should not be separately accounted for as a bifurcated derivative instrument.

•Additional Interest Features: The Notes may result in additional interest if the Company fails to timely file any document or report that the Company is required to file with the SEC pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The Company will pay additional interest on the notes at a rate equal to 0.25% to 0.50% per annum based on the principal amount of notes outstanding for each day the Company failure to file has occurred or the notes are not otherwise freely tradable. Further, if the notes are assigned a restricted CUSIP number or the notes are not otherwise freely tradable pursuant to Rule 144 under the Securities Act by holders other than our affiliates or holders that were our affiliates at any time during the three months immediately preceding as of the 385th day after the last date of original issuance of the notes offered hereby, the Company will pay additional interest on the notes at a rate equal to (i) 0.25% to 0.50% per annum based on the principal amount of notes outstanding for each day until the restrictive legend has been removed from the notes, the notes are assigned an unrestricted CUSIP and the notes are freely tradable. The Company concluded that the interest feature is unrelated to the credit risk and should be bifurcated from the Notes, however, the Company assessed the probabilities of triggering events occurring under these features and does not expect to trigger the aforementioned events. These events will continue to be monitored to determine whether the interest feature will be bifurcated if it has value.

As of December 31, 2022, the carrying value of the Notes was $575.0 million, had an unamortized discount of zero, and the fair value of the liability was $575.0 million. The Company recorded interest expense of approximately $1.3 million related to the Notes for the year ended December 31, 2022.

Royalty-Backed Loan

On June 19, 2020, as a result of the acquisition, the Company assumed Progenics’ outstanding debt as of such date in the amount of $40.2 million. Progenics, through a wholly-owned subsidiary MNTX Royalties Sub LLC (“MNTX Royalties”), entered into a $50.0 million loan agreement (the “Royalty-Backed Loan”) with a fund managed by HealthCare Royalty Partners III, L.P. (“HCRP”) on November 4, 2016. The Royalty-Backed Loan bore interest at a per annum rate of 9.5% and was scheduled to mature on June 30, 2025.

On March 31, 2021, the Company voluntarily repaid in full the entire outstanding principal on the Royalty-Backed Loan in the amount of $30.9 million, which included a prepayment amount of $0.5 million, and terminated the agreement governing the Royalty-Backed Loan. The Company recorded a gain on extinguishment of debt of $0.9 million related to the write-off of an unamortized debt premium offset by the prepayment amount.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Derivative Instruments

12 Months Ended

Dec. 31, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments

The Company has used interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. In March 2020, the Company entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. The average fixed LIBOR rate on the interest rate swaps was approximately 0.82%. This agreement involved the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the agreement without an exchange of the underlying principal amount. The interest rate swaps were designated as cash flow hedges. In accordance with hedge accounting, the interest rate swaps are recorded on the Company’s consolidated balance sheets at fair value, and changes in the fair value of the swap agreements were recorded to other comprehensive loss and reclassified to interest expense in the period during which the hedged transaction affected earnings or it will become probable that the forecasted transaction would not occur.

On December 2, 2022, the Company voluntarily terminated the interest rate swap contracts in connection with the refinancing of debt. Upon termination, the Company received approximately $5.6 million in cash and the remaining balance of approximately $5.5 million in accumulated other comprehensive income (loss) related to the interest rate swap contracts were reclassified into earnings.

The following table presents the location and fair value amounts of derivative instruments reported in the consolidated balance sheet:

(in thousands)

December 31, 2022

December 31, 2021

Derivatives type

Classification

Assets:

Interest rate swap

Other long-term assets

—

357

Accumulated Other Comprehensive Loss

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Accumulated Other Comprehensive Loss

The components of Accumulated Other Comprehensive Loss, net of tax of zero and $0.1 million for the year ended December 31, 2022 and 2021, respectively, consisted of the following:


(in thousands)	Foreign currency translation		Unrealized loss on cash flow hedges		Accumulated other comprehensive loss
Balance at January 1, 2022	$	(754)	$	269	$	(485)
Other comprehensive income (loss) before reclassifications	(505)		5,838		5,333
Amounts reclassified to earnings	—		(6,107)		(6,107)
Balance at December 31, 2022	$	(1,259)	$	—	$	(1,259)

Balance at January 1, 2021	$	(630)	$	(1,418)	$	(2,048)
Other comprehensive income (loss) before reclassifications	(124)		962		838
Amounts reclassified to earnings	—		725		725
Balance at December 31, 2021	$	(754)	$	269	$	(485)

Stock-Based Compensation

12 Months Ended

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

Equity Incentive Plans

As of December 31, 2022, the Company’s approved equity incentive plans included the 2015 Equity Incentive Plan (“2015 Plan”), the 2013 Equity Incentive Plan (“2013 Plan”), and the 2008 Equity Incentive Plan (“2008 Plan”). These plans are administered by the Board of Directors and permit the granting of stock options, stock appreciation rights, restricted stock, restricted stock units and dividend equivalent rights to employees, officers, directors and consultants of the Company.

The Company has certain stock option and restricted stock awards outstanding under each of its equity incentive plans but, upon adoption of the 2015 Plan, no longer grants new equity awards under its 2008 and 2013 Plans. The Company adopted its 2015 Plan in June 2015 and subsequently amended the plan in April 2016, 2017, 2019, 2021 and 2022 which increased the common stock reserved for issuance under the plan to an aggregate 10,930,277 shares. The Company assumed Progenics equity plans due to the acquisition as discussed in Note 1, “Description of Business”. The Company no longer grants new equity awards under the Progenics equity plans.

Stock-based compensation expense recognized in the consolidated statements of operations is summarized below:


	Year Ended December 31,
(in thousands)	2022		2021		2020
Cost of goods sold	$	4,422	$	2,370	$	2,820
Sales and marketing	6,185		2,472		1,821
General and administrative	14,876		9,092		7,333
Research and development	3,779		2,000		2,101
Total stock-based compensation expense	$	29,262	$	15,934	$	14,075

Stock Options

Stock option awards under the 2015 Plan are granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. All option awards have a ten-year contractual term.

A summary of option activity for 2022 is presented below:


	Total Stock Options	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Balance at January 1, 2022	972,939	$	18.73	4.7	10,145,135
Options granted	317,789	$	53.55
Options exercised	(397,822)	$	20.07
Options cancelled and forfeited	(18,157)	$	38.20
Outstanding at December 31, 2022	874,749	$	30.37	5.8	19,058,224
Vested and expected to vest at December 31, 2022	874,749	$	30.37	5.8	19,058,224
Exercisable at December 31, 2022	517,424	$	17.83	3.6	17,141,202

The table below summarizes the key weighted-average assumptions used in valuing stock options granted:


	Year Ended December 31,
	2022		2021		2020
Expected volatility	62.1	%	—	%	71.1	%
Risk-free interest rate	2.0	%	—	%	0.3	%
Expected life (in years)	6.0		—		3.5
Expected dividend yield	—		—		—

During the years ended December 31, 2022, 2021 and 2020, 397,822, 318,662 and 8,868 options were exercised having aggregate intrinsic values of $13.1 million, $1.6 million and $0.1 million, respectively.

As of December 31, 2022, there was $7.0 million of unrecognized compensation expense related to outstanding stock options, which is expected to be recognized over a weighted-average period of 2.2 years.

Restricted Stock

A summary of restricted stock awards and restricted stock units activity for 2022 is presented below:


	Shares	Weighted- Average Grant Date Fair Value Per Share
Nonvested balance at January 1, 2022	1,330,374	$	19.04
Granted	649,672	$	51.51
Vested	(624,069)	$	19.11
Forfeited	(105,985)	$	30.81
Nonvested balance at December 31, 2022	1,249,992	$	34.65

Restricted stock generally vest over 3 years. As of December 31, 2022, there was $30.1 million of unrecognized compensation expense related to outstanding restricted stock, which is expected to be recognized over a weighted-average period of 2.0 years.

The weighted average grant-date fair value for restricted stock granted during the fiscal years ended December 31, 2022, 2021 and 2020 was $51.51, $20.14 and $15.00 per share, respectively. The total fair value of restricted stock vested in fiscal years 2022, 2021 and 2020 was $11.9 million, $8.8 million and $7.6 million, respectively.

Total Stockholder Return Restricted Stock Awards (“TSR Awards”)

During the years ended December 31, 2022, 2021 and 2020, the Company granted total stockholder return (“TSR”) Awards that include a three-year market condition where the performance measurement period is three years. Vesting of the TSR Awards is based on the Company’s level of attainment of specified TSR targets relative to the percentage appreciation of a specified index of companies for the respective three-year period and is also subject to the continued employment of the grantees. The number of shares

that are earned over the performance period ranges from 0% to 200% of the initial award. The fair value of these awards are based on a Monte Carlo simulation valuation model with the following assumptions:


	Year Ended December 31,
	2022		2021		2020
Expected volatility	56.6	%	54.0	%	53.3	%
Risk-free interest rate	1.7	%	0.3	%	0.7	%
Expected life (in years)	2.8		2.8		2.8
Expected dividend yield	—		—		—

A summary of TSR Award activity for 2022 is presented below:


	Shares	Weighted- Average Grant Date Fair Value Per Share
Nonvested balance at January 1, 2022	590,073	$	30.49
Granted	304,212	$	95.31
Vested	(220,339)	$	39.92
Forfeited	(15,071)	$	31.30
Nonvested balance at December 31, 2022	658,875	$	48.58

As of December 31, 2022, there was $18.9 million of unrecognized compensation expense related to outstanding performance restricted stock which is expected to be recognized over a weighted-average period of 2.0 years.

The weighted average grant-date fair value for TSR Awards granted during the fiscal years ended December 31, 2022, 2021 and 2020 was $95.31, $31.25 and $23.43 per share, respectively. The total fair value of TSR Awards vested in fiscal years 2022, 2021 and 2020 was $8.8 million, $2.0 million and zero, respectively.

Common Stock Repurchases

In December 2022, the Company’s Board of Directors authorized the repurchase of up to $150.0 million in aggregate amount of the Company’s common stock under certain circumstances. The Company used approximately $75.0 million of the net proceeds from the Notes to repurchase shares of their common stock from purchasers of the Notes in privately negotiated transactions effected with or through one of the initial purchasers or its affiliate. The purchase price per share of the common stock repurchased in such transactions was equal to the closing sale price per share of the Company’s common stock on the date of the offering memorandum used for the Notes, which was $56.01 per share. Following this initial repurchase, The Company may from time to time repurchase additional shares of their common stock. In the year ended December 31, 2022, the Company purchased approximately 1.3 million shares of their outstanding common stock for $75.0 million as part of the program. The Company did not purchase any shares of their outstanding common stock in the years ended December 31, 2021 and 2020, respectively.

Leases

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Leases

The Company determines if an arrangement is a lease at inception. The Company has operating and finance leases for vehicles, corporate offices and certain equipment.

Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease agreements with lease and non-lease components are accounted for separately. As the Company’s leases do not provide an implicit rate, the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company assumed two operating leases as a result of the Progenics acquisition related to office space at the World Trade Center in New York City, pursuant to a lease agreement expiring in September 2030 (the “WTC Lease”), and a radiopharmaceutical manufacturing facility in Somerset, New Jersey, under a sublease agreement expiring in November 2028, which were recorded as of June 19, 2020, for $18.6 million and $0.6 million, respectively. The Company entered into an operating lease related to office space in Somerset, New Jersey, under a lease agreement expiring in August 2026, which was recorded in October 2021 for $0.7 million. The Company entered into an operating

lease agreement in February 2022 to lease office space in Bedford, Massachusetts, under a lease agreement expiring in June 2031, which commenced and was recorded in December 2022 for $11.0 million.

Leases with an initial term of 12 months or less are not recorded on the balance sheet as the Company has elected to apply the short-term lease exemption. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.

Operating and finance lease assets and liabilities are as follows:


(in thousands)	Classification	December 31, 2022		December 31, 2021
Assets
Operating	Other long-term assets	$	19,033	$	8,788
Finance	Property, plant and equipment, net	582		556
Total leased assets		$	19,615	$	9,344
Liabilities
Current
Operating	Accrued expenses and other liabilities	$	2,177	$	1,599
Finance	Current portion of long-term debt and other borrowings	354		392
Noncurrent
Operating	Other long-term liabilities	25,442		16,546
Finance	Long-term debt, net and other borrowings	231		299
Total leased liabilities		$	28,204	$	18,836

In the third quarter of 2021, with respect to the office space in the World Trade Center, the Company negotiated a sublease agreement with an unrelated third party that was signed on October 11, 2021 (the “Sublease”) and has a term of nine years, which represents the remaining term of the WTC Lease. Both the WTC Lease and the Sublease are classified by the Company as operating leases. As a result of the negotiations of the Sublease, the Company determined that an impairment triggering event had occurred. Accordingly, the Company performed an undiscounted cash flow analysis related to the asset group as of September 30, 2021. Based on the undiscounted cash flow analysis, the Company determined that the asset group, including the ROU asset, had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair value of the asset group based on its discounted cash flows. The carrying value exceeded the fair value and, as a result, the Company recorded a non-cash impairment of $9.5 million for the year ended December 31, 2021 in general and administrative expenses in the consolidated statements of operations.

The components of lease expense were as follows:


(in thousands)	Year Ended December 31, 2022		Year Ended December 31, 2021
Operating lease expense	$	1,797	$	2,312
Finance lease expense
Amortization of ROU assets	426		330
Interest on lease liabilities	28		28
Short-term lease expense	—		8
Total lease expense	$	2,251	$	2,678

Other information related to leases were as follows:


		December 31, 2022		December 31, 2021
Weighted-average remaining lease term (Years):
Operating leases		7.9		8.6
Finance leases		1.9		2.2
Weighted-average discount rate:
Operating leases		4.8%		4.4%
Finance leases		4.4%		4.6%

(in thousands)		Year Ended December 31, 2022		Year Ended December 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	2,440	$	2,071
Operating cash flows from finance leases		28		28
Financing cash flows from finance leases		384		339
ROU assets obtained in exchange for lease obligations:
Operating leases		11,019		683
Finance leases		582		556

Future minimum lease payments under non-cancellable leases as of December 31, 2022 were as follows:


(in thousands)	Operating Leases		Finance Leases
2023	$	3,462	$	366
2024	3,887		203
2025	4,147		49
2026	4,245		—
2027	4,381		—
Thereafter	13,599		—
Total future minimum lease payments	33,721		618
Less: interest	6,102		33
Total	$	27,619	$	585

Leases

The Company determines if an arrangement is a lease at inception. The Company has operating and finance leases for vehicles, corporate offices and certain equipment.

lease agreement in February 2022 to lease office space in Bedford, Massachusetts, under a lease agreement expiring in June 2031, which commenced and was recorded in December 2022 for $11.0 million.

Operating and finance lease assets and liabilities are as follows:


(in thousands)	Classification	December 31, 2022		December 31, 2021
Assets
Operating	Other long-term assets	$	19,033	$	8,788
Finance	Property, plant and equipment, net	582		556
Total leased assets		$	19,615	$	9,344
Liabilities
Current
Operating	Accrued expenses and other liabilities	$	2,177	$	1,599
Finance	Current portion of long-term debt and other borrowings	354		392
Noncurrent
Operating	Other long-term liabilities	25,442		16,546
Finance	Long-term debt, net and other borrowings	231		299
Total leased liabilities		$	28,204	$	18,836

The components of lease expense were as follows:


(in thousands)	Year Ended December 31, 2022		Year Ended December 31, 2021
Operating lease expense	$	1,797	$	2,312
Finance lease expense
Amortization of ROU assets	426		330
Interest on lease liabilities	28		28
Short-term lease expense	—		8
Total lease expense	$	2,251	$	2,678

Other information related to leases were as follows:


		December 31, 2022		December 31, 2021
Weighted-average remaining lease term (Years):
Operating leases		7.9		8.6
Finance leases		1.9		2.2
Weighted-average discount rate:
Operating leases		4.8%		4.4%
Finance leases		4.4%		4.6%

(in thousands)		Year Ended December 31, 2022		Year Ended December 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	2,440	$	2,071
Operating cash flows from finance leases		28		28
Financing cash flows from finance leases		384		339
ROU assets obtained in exchange for lease obligations:
Operating leases		11,019		683
Finance leases		582		556

Future minimum lease payments under non-cancellable leases as of December 31, 2022 were as follows:


(in thousands)	Operating Leases		Finance Leases
2023	$	3,462	$	366
2024	3,887		203
2025	4,147		49
2026	4,245		—
2027	4,381		—
Thereafter	13,599		—
Total future minimum lease payments	33,721		618
Less: interest	6,102		33
Total	$	27,619	$	585

Other Assets

12 Months Ended

Dec. 31, 2022

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Assets

Other assets are comprised of the following:


	December 31,
(in thousands)	2022		2021
Prepaid Expenses	$	12,887	$	10,113
Current Contingent Asset (Note 4)	—		2,500
Other Current Assets	205		205
Total other current assets	$	13,092	$	12,818

ROU Asset (Note 17)	$	19,033	$	8,788
Long-term Contingent Asset (Note 4)	—		6,800
Other Long-Term Assets	15,322		23,170
Total other long-term assets	$	34,355	$	38,758

Net Income (Loss) Per Common Share

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Net Income (Loss) Per Common Share

A summary of net income (loss) per common share is presented below:


	Year Ended December 31,
(in thousands, except per share amounts)	2022		2021		2020
Net income (loss)	$	28,067	$	(71,279)	$	(13,473)

Basic weighted-average common shares outstanding	68,487		67,486		54,134
Effect of dilutive stock options	439		—		—

Effect of dilutive restricted stock	1,745		—		—
Diluted weighted-average common shares outstanding	70,671		67,486		54,134

Basic income (loss) per common share	$	0.41	$	(1.06)	$	(0.25)
Diluted income (loss) per common share	$	0.40	$	(1.06)	$	(0.25)

Antidilutive securities excluded from diluted net income (loss) per common share	358		2,893		3,175

Impact of the Notes

The Company considered whether the notes are participating securities through the two-class method. The Company determined that if a cash dividend is paid that is greater than the then stock price, the holder of notes will receive cash on an if-converted basis. While this feature is considered to be a participating right; basic earnings per share is only impacted if the Company’s earning exceeds the current share price, regardless of whether such dividend is declared. During the year ended December 31, 2022, no such dividend was declared. In addition, the Company is required to settle the principal amount of the Notes in cash upon conversion, and therefore, the Company uses the if-converted method for calculating any potential dilutive effect of the conversion option on diluted net income per share, if applicable, unless the application of the two-class method is dilutive. The conversion option will have a dilutive impact on net income per share of Common Stock when the average market price per share of the Company's Common Stock for a given period exceeds the conversion price of the Notes of $79.81 per share. During the year ended December 31, 2022, the weighted average price per share of the Company's Common Stock was below the conversion price of the Notes.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Purchase Commitments

The Company has entered into purchasing arrangements in which minimum quantities of goods or services have been committed to be purchased on an annual basis.

As of December 31, 2022, future payments required under purchase commitments are as follows:


(in thousands)	Amount
2023	5,716
2024	2,716
2025	2,716
2026	2,716
2027 and thereafter	2,716
Total	$	16,580

The Company has entered into agreements which contain certain percentage volume purchase requirements. The Company has excluded these future purchase commitments from the table above since there are no minimum purchase commitments or payments under these agreements.

License Agreements

The Company has entered into license agreements in which fixed payments have been committed to be paid on an annual basis.

As of December 31, 2022, future fixed payments required under license agreements are $0.1 million. The Company may be required to pay additional amounts up to approximately $200.0 million in contingent payments under the Company’s license agreements. These contingent payments include potential milestone or contractual payment obligations contingent upon the

achievement or occurrence of future milestones or events and the amounts and timing of such potential obligations are unknown or uncertain.

Legal Proceedings

From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The costs and outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its consolidated financial statements.

As of December 31, 2022, the Company did not have any material ongoing litigation to which the Company was a party.

401(k) Plan	12 Months Ended
401(k) Plan	Dec. 31, 2022
Retirement Benefits [Abstract]
401(k) Plan	401(k) Plan The Company maintains a qualified 401(k) plan (the “401(k) Plan”) for its U.S. employees. The 401(k) Plan covers U.S. employees who meet certain eligibility requirements. Under the terms of the 401(k) Plan, the employees may elect to make tax-deferred contributions through payroll deductions within statutory and plan limits, and the Company may elect to make non-elective discretionary contributions. The Company may also make optional contributions to the 401(k) Plan for any plan year at its discretion. Expense recognized by the Company for matching contributions made to the 401(k) Plan was $3.1 million, $2.6 million and $0.8 million for the years ended December 31, 2022, 2021 and 2020, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI https://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Acquisition of Assets	12 Months Ended
Acquisition of Assets	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisition of Assets	Acquisition of Assets In December 2022, the Company made upfront payments of $260.0 million to POINT as a part of an asset acquisition with the potential for additional milestone payments of approximately $1.8 billion between the two licensed assets based on U.S. Food and Drug Administration (“FDA”) approval and net sales and commercial milestones. Under the terms of the PNT2002 License Agreement, Lantheus Two, LLC paid POINT an upfront cash payment of $250.0 million, and could pay up to an additional $281.0 million in milestone payments upon the achievement of specified U.S. and ex-U.S. regulatory milestones related to PNT2002. POINT is also eligible to receive up to $1.3 billion in sales milestone payments upon the achievement of specified annual sales thresholds of PNT2002. Under the terms of the PNT2003 License Agreement, Lantheus Three, LLC paid POINT an upfront cash payment of $10.0 million, and could pay up to an additional $34.5 million in milestone payments upon the achievement of specified U.S. and ex-U.S. regulatory milestones related to PNT2003. POINT is also eligible to receive up to $275.0 million in sales milestone payments upon the achievement of specified annual sales thresholds of PNT2003. Additionally, the Company will pay POINT royalties on net sales, beyond certain financial thresholds and subject to conditions, of 20% for PNT2002 and 15% for PNT2003. Costs of IPR&D projects acquired as part of an asset acquisition that have no alternative future use are expensed when incurred, and therefore, a charge of $260.0 million was recognized in research and development expenses during the year ended December 31, 2022.

Segment Information	12 Months Ended
Segment Information	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Information	Segment InformationIn the first quarter of 2021, the Company completed the evaluation of its operating and reporting structure, including the impact on the Company’s business of the acquisition of Progenics described in Notes 1 and 8, and the sale of the Puerto Rico subsidiary in the first quarter, which resulted in a change in operating and reportable segments. The Company now operates as one business segment: the development, manufacture and sale of innovative imaging diagnostics, radiotherapeutics, and artificial intelligence solutions designed to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. This conclusion reflects the Company’s focus on the performance of the business on a consolidated worldwide basis. The results of this operating segment are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s chief operating decision maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Subsequent Event	12 Months Ended
Subsequent Event	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Event	Subsequent EventOn February 6, 2023, the Company acquired Cerveau Technologies, Inc. (“Cerveau”). Cerveau’s asset is MK-6240, a second-generation F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s disease that will expand our Pharma Services business. Under the terms of the agreement, Lantheus paid an upfront payment of $35 million and potentially will pay additional development and commercial milestone payments. Additionally, Lantheus will pay double-digit royalty payments for research revenue and commercial sales. Research revenue is derived from existing partnerships with pharmaceutical companies that use the imaging agent in clinical trials and includes milestone and dose-related payments. Structured as a stock purchase, the agreement specifies, among other things, that the seller will also provide transition and clinical development services for a prescribed time following the closing of the transaction.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation and Principles of ConsolidationThe accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

Revenue Recognition

Accounts Receivable, net

Accounts Receivable, netAccounts receivable consist of amounts billed and currently due from customers. The Company maintains an allowance for doubtful accounts for estimated losses. In determining the allowance, consideration includes the probability of recoverability based on past experience and general economic factors. Certain accounts receivable may be fully reserved when the Company becomes aware of any specific collection issues. The Company periodically reviews the aging of receivables, payment history and customer creditworthiness to determine if adjustments to the allowance for bad debt is necessary. Allowance for bad debt has been immaterial for all years presented.

Income Taxes

Net Income (Loss) per Common Share

Cash and Cash Equivalents

Cash and cash equivalents include savings deposits, certificates of deposit and money market funds that have original maturities of three months or less when purchased.

Restricted Cash

Concentration of Risks and Limited Suppliers

Inventory

The Company assesses the recoverability of inventory to determine whether adjustments for excess and obsolete inventory are required. Inventory that is in excess of future requirements is written down to its estimated net realizable value based on product shelf life, forecasted demand and other factors.Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed as incurred.

Property, Plant and Equipment, net


Class						Range of Estimated Useful Lives
Buildings						10 - 50 years
Land improvements						15 - 40 years
Machinery and equipment						3 - 15 years
Furniture and fixtures						15 years
Leasehold improvements						Lesser of lease term or 15 years
Computer software						3 - 5 years

Business Combinations

Goodwill

Intangible and Long-Lived Assets

Contingencies

Convertible Notes

Fair Values of Financial Instruments

Contingent Consideration Liabilities

Derivative Instruments

The Company has used interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. To qualify for hedge accounting, the hedging instrument must be highly effective at reducing the risk from the exposure being hedged. Further, the Company must formally document the hedging relationship at inception and, on at least a quarterly basis, continually reevaluate the relationship to ensure it remains highly effective throughout the life of the hedge. The Company does not enter into derivative financial instruments for speculative or trading purposes.

Advertising and Promotion Costs

Advertising and Promotion CostsAdvertising and promotion costs are expensed as incurred.

Research and Development

Foreign Currency

Stock-Based Compensation

Comprehensive Income (Loss)

Asset Retirement Obligations

Self-Insurance Reserves

Recent Accounting Pronouncements

The Company has not adopted any new accounting standards during the year ended December 31, 2022.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Schedule of product concentration risk

The following table sets forth revenues for each of the Company’s products representing 10% or more of revenues:


	Year Ended December 31,
	2022		2021		2020
PYLARIFY	56.4	%	10.2	%	—	%
DEFINITY	26.2	%	54.7	%	62.8	%
TechneLite	9.5	%	21.5	%	25.4	%

Schedule of estimated useful lives of major classes of depreciable assets

The estimated useful lives of the major classes of depreciable assets are as follows:


Class						Range of Estimated Useful Lives
Buildings						10 - 50 years
Land improvements						15 - 40 years
Machinery and equipment						3 - 15 years
Furniture and fixtures						15 years
Leasehold improvements						Lesser of lease term or 15 years
Computer software						3 - 5 years

Property, plant and equipment, net, consisted of the following:


	December 31,
(in thousands)	2022		2021
Land	$	13,450	$	13,450
Buildings	76,329		73,559
Machinery, equipment and fixtures	92,604		83,608
Computer software	25,864		24,384
Construction in progress	14,047		10,686
	222,294		205,687
Less: accumulated depreciation and amortization	(100,128)		(88,915)
Total property, plant and equipment, net	$	122,166	$	116,772

Schedule of other loss (income)

Other loss (income) consisted of the following:


	Year Ended December 31,
(in thousands)	2022		2021		2020
Foreign currency losses (gains)	$	256	$	274	$	260
Tax indemnification expense (income), net	9,554		7,121		(2,218)
Interest income	(2,613)		(45)		(238)
Interest rate swap termination	(5,494)		—		—
Other	—		—		(2)
Total other loss (income)	$	1,703	$	7,350	$	(2,198)

Revenue from Contracts with Customers (Tables)

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

The following table summarizes revenue by revenue source as follows:


	Year Ended December 31,
Major Products/Service Lines (in thousands)	2022		2021		2020
Product revenue, net(1)	$	887,038	$	400,356	$	327,695
License and royalty revenues(2)	48,023		24,852		11,715
Total revenues	$	935,061	$	425,208	$	339,410

______________________________

(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG.

Revenue by product category on a net basis is as follows:


	Year Ended December 31,
(in thousands)	2022		2021		2020
DEFINITY	$	244,993	$	232,759	$	195,865
TechneLite	88,864		91,293		84,945
Other precision diagnostics	22,825		26,973		36,824
Total precision diagnostics	356,682		351,025		317,634
PYLARIFY	527,405		43,414		—
Other radiopharmaceutical oncology	4,102		5,473		10,022
Total radiopharmaceutical oncology	531,507		48,887		10,022
Strategic Partnerships and other revenue	46,872		25,296		11,754
Total revenues	$	935,061	$	425,208	$	339,410

Schedule of valuation and qualifying accounts

An analysis of the amount of, and change in, reserves is summarized as follows:


(in thousands)	Rebates and Allowances
Balance, January 1, 2021	$	9,350
Provision related to current period revenues	25,772
Adjustments relating to prior period revenues	14
Payments or credits made during the period	(24,159)
Balance, December 31, 2021	10,977
Provision related to current period revenues	26,683
Adjustments relating to prior period revenues	70
Payments or credits made during the period	(24,331)
Balance, December 31, 2022	$	13,399

Schedule of contracts with customer

The Company recognized certain revenues as follows:


	Year Ended December 31,
(in thousands)	2022		2021
Amounts included in the contract liability at the beginning of the period	$	244	$	33

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Schedule of assets and liabilities measured at fair value on a recurring basis

The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:


	December 31, 2022
(in thousands)	Total Fair Value		Level 1		Level 2		Level 3
Assets:
Money market	$	342,646	$	342,646	$	—	$	—


Total assets	$	342,646	$	342,646	$	—	$	—
Liabilities:

Contingent consideration liabilities	$	111,600	$	—	$	—	$	111,600
Total liabilities	$	111,600	$	—	$	—	$	111,600


	December 31, 2021
(in thousands)	Total Fair Value		Level 1		Level 2		Level 3
Assets:
Money market	$	40,140	$	40,140	$	—	$	—
Interest rate swaps	357		—		357		—
Contingent receivable	9,300		—		—		9,300
Total assets	$	49,797	$	40,140	$	357	$	9,300
Liabilities:

Contingent consideration liabilities	86,200		—		—		86,200
Total liabilities	$	86,200	$	—	$	—	$	86,200

Fair value measurement inputs and valuation techniques

The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs as of December 31, 2022.


	Fair Value as of						Assumptions
(in thousands)	December 31, 2022		December 31, 2021		Valuation Technique	Unobservable Input	December 31, 2022	December 31, 2021
Contingent receivable:
Regulatory milestone	$	—	$	2,500	Probability adjusted discounted cash flow model	Period of expected milestone achievement	N/A	2022
						Probability of success	0%	70	%
						Discount rate	N/A	17	%
Royalties	—		6,800		Probability adjusted discounted cash flow model
						Probability of success	0%	10% - 60%
						Discount rate	N/A	17	%
Total	$	—	$	9,300


	Fair Value as of						Assumptions
(in thousands)	December 31, 2022		December 31, 2021		Valuation Technique	Unobservable Input	December 31, 2022		December 31, 2021
Contingent consideration liability:
Net sales targets - PYLARIFY (CVRs)	$	99,700	$	73,200	Probability adjusted discounted cash flow model (as of 12/31/2022) Monte Carlo simulation (as of 12/31/2021)	Period of expected milestone achievement and sales targets	2022 - 2023		2022 - 2023
						Probability of success	100	%	N/A
						Discount rate	N/A		17	%
1095 commercialization milestone	1,700		1,900		Probability adjusted discounted cash flow model
						Period of expected milestone achievement	2026		2026
						Probability of success	40	%	40	%
						Discount rate	3.8	%	1.3	%



Net sales targets - AZEDRA and 1095	10,200		11,100		Monte Carlo simulation
						Probability of success and sales targets	20% - 100%		40% - 100%
						Discount rate	16% - 17%		16% - 17%
Total	$	111,600	$	86,200

Schedule of financial instruments with significant Level 3 inputs

For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:


	Financial Assets				Financial Liabilities
(in thousands)	Years Ended December 31,				Years Ended December 31,
	2022		2021		2022		2021
Fair value, beginning of period	$	9,300	$	11,300	$	86,200	$	15,800

Changes in fair value included in net income (loss)	(9,300)		(2,000)		25,400		70,400

Fair value, end of period	$	—	$	9,300	$	111,600	$	86,200

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Schedule of components of income (loss) before provision (benefit) for income taxes

The components of income (loss) before provision (benefit) for income taxes consists of the following:


	Year Ended December 31,
(in thousands)	2022		2021		2020
U.S.	$	29,012	$	(76,389)	$	(5,495)
International	(2,293)		1,351		(5,984)
Income (loss) before income taxes	$	26,719	$	(75,038)	$	(11,479)

Schedule of provision (benefit) for income taxes

The Company’s provision (benefit) for income taxes consists of the following:


	Year Ended December 31,
(in thousands)	2022		2021		2020
Current
Federal	$	42,532	$	—	$	—
State	4,302		(8,166)		3,158
International	(166)		(30)		170
	46,668		(8,196)		3,328
Deferred
Federal	(39,920)		1,048		(1,506)
State	(8,315)		3,058		(178)
International	219		331		350
	(48,016)		4,437		(1,334)
Income tax (benefit) expense	$	(1,348)	$	(3,759)	$	1,994

Schedule of reconciliation of income taxes at the U.S. federal statutory rate to the actual income taxes

The reconciliation of income taxes at the U.S. federal statutory rate to the income tax (benefit) expense is as follows:


	Year Ended December 31,
(in thousands)	2022		2021		2020
U.S. statutory rate	$	5,611	$	(15,758)	$	(2,411)
Permanent items	2,309		1,764		1,176
Acquisition costs - Progenics	—		—		2,723
Recognition of deferred tax asset - assets held for sale	—		—		(3,000)
Section 162(m)	247		1,028		717
Uncertain tax positions	(12,629)		(8,952)		2,818
Other tax credits	(4,085)		(990)		(1,065)
State and local taxes	67		656		1,457
Impact on deferred taxes of change in tax rate	4,169		3,049		—
Non-deductible changes in fair value of contingent assets and liabilities	5,422		15,015		230
Foreign tax rate differential	68		23		(254)
Valuation allowance	(30)		(400)		(318)
Benefit of windfall related to stock compensation	(4,612)		(1,164)		(128)
Change in indemnification deferred tax asset	2,343		1,786		(590)
Other	(228)		184		639
Income tax (benefit) expense	$	(1,348)	$	(3,759)	$	1,994

Schedule of components of deferred incomes tax assets (liabilities)

The components of deferred income tax assets (liabilities) are as follows:


	December 31,
(in thousands)	2022		2021
Deferred Tax Assets
Federal benefit of state tax liabilities	$	1,739	$	4,292
Reserves, accruals and other	31,532		27,159
Inventory obsolescence	919		297
Capitalized research and development	79,946		768
Amortization of intangibles other than goodwill	—		502
Net operating loss carryforwards	88,014		122,944
Depreciation	—		1,102
Deferred tax assets	202,150		157,064
Deferred Tax Liabilities
Reserves, accruals and other	(5,354)		(3,026)
Intangible assets	(80,770)		(87,351)
Amortization of intangibles other than goodwill	(385)		—
Depreciation	(1,469)		—
Deferred tax liability	(87,978)		(90,377)
Less: valuation allowance	(3,525)		(3,923)
	$	110,647	$	62,764
Recorded in the accompanying consolidated balance sheets as:
Noncurrent deferred tax assets, net	$	110,647	$	62,764

Schedule of reconciliation of the Company's changes in uncertain tax positions

A reconciliation of the Company’s changes in uncertain tax positions for 2022 and 2021 is as follows:


(in thousands)	Amount
Balance of uncertain tax positions as of January 1, 2021	$	5,292
Additions related to current year tax positions	—
Reductions related to prior year tax positions	(188)
Settlements	(1,446)
Lapse of statute of limitations	—
Balance of uncertain tax positions as of December 31, 2021	3,658
Additions related to current year tax positions	—
Reductions related to prior year tax positions	(1,180)
Settlements	(306)
Lapse of statute of limitations	(692)
Balance of uncertain tax positions as of December 31, 2022	$	1,480

Inventory (Tables)

12 Months Ended

Dec. 31, 2022

Inventory Disclosure [Abstract]

Schedule of inventory

Inventory consisted of the following:


	December 31,
(in thousands)	2022		2021
Raw materials	$	19,987	$	15,505
Work in process	8,234		13,042
Finished goods	7,254		6,582
Total inventory	$	35,475	$	35,129

Property, Plant & Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2022

Property, Plant and Equipment [Abstract]

Schedule of property, plant, and equipment, net

The estimated useful lives of the major classes of depreciable assets are as follows:


Class						Range of Estimated Useful Lives
Buildings						10 - 50 years
Land improvements						15 - 40 years
Machinery and equipment						3 - 15 years
Furniture and fixtures						15 years
Leasehold improvements						Lesser of lease term or 15 years
Computer software						3 - 5 years

Property, plant and equipment, net, consisted of the following:


	December 31,
(in thousands)	2022		2021
Land	$	13,450	$	13,450
Buildings	76,329		73,559
Machinery, equipment and fixtures	92,604		83,608
Computer software	25,864		24,384
Construction in progress	14,047		10,686
	222,294		205,687
Less: accumulated depreciation and amortization	(100,128)		(88,915)
Total property, plant and equipment, net	$	122,166	$	116,772

Business Combinations (Tables)

12 Months Ended

Dec. 31, 2022

Business Combination and Asset Acquisition [Abstract]

Schedule of business acquisition

The acquisition date fair value of the consideration transferred in the acquisition consisted of the following:


(in thousands)	Amount
Issuance of common stock	$	398,110
Fair value of replacement stock options	7,125
Fair value of bridge loan settled at close	10,074
Fair value of contingent considerations (CVRs)	3,700
Total consideration transferred	$	419,009

Schedule of fair value disclosure of asset and liability

The related impact to net loss that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial to the consolidated financial statements.


(in thousands)	Amounts Recognized as of Acquisition Date (as previously reported)		Measurement Period Adjustments		Amounts Recognized as of Acquisition Date (as adjusted)
Cash and cash equivalents	$	15,421	$	—	$	15,421
Accounts receivable	5,787		—		5,787
Inventory	915		160		1,075
Other current assets	3,250		434		3,684
Property, plant and equipment	14,972		—		14,972
Identifiable intangible assets (weighted-average useful life):
Currently marketed product (15 years)	142,100		800		142,900
Licenses (11.5 years)	87,500		(1,700)		85,800
Developed technology (9 years)	3,000		(600)		2,400
IPR&D	150,900		200		151,100
Other long-term assets	37,631		—		37,631
Accounts payable	(1,616)		—		(1,616)
Accrued expenses and other liabilities	(8,207)		(80)		(8,287)
Other long-term liabilities	(30,778)		(380)		(31,158)
Long-term debt and other borrowings	(40,200)		—		(40,200)
Deferred tax liabilities	(3,717)		(2,258)		(5,975)
Goodwill	42,051		3,424		45,475
Total consideration transferred	$	419,009	$	—	$	419,009

Schedule pro forma financial information

The following unaudited pro forma financial information presents the Company’s results as if the Progenics Acquisition had occurred on January 1, 2019:


	Year Ended December 31, 2020
(in thousands)	Amount
Pro forma revenue	$	350,315
Pro forma net loss	$	29,190

Sale of Puerto Rico Subsidiary (Tables)

12 Months Ended

Dec. 31, 2022

Discontinued Operations and Disposal Groups [Abstract]

Disclosure Of Assets and Liabilities Held For Sale

The following table summarizes the major classes of assets and liabilities sold as of January 29, 2021, the date of sale:



(in thousands)	January 29, 2021
Current Assets:
Cash and cash equivalents	$	540
Accounts receivable, net	1,959
Inventory	530
Other current assets	65
Total current assets	3,094
Non-Current Assets:
Property, plant & equipment, net	780
Intangibles, net	96
Other long-term assets	774
Total assets held for sale	$	4,744

Current Liabilities:
Accounts payable	$	185
Accrued expense and other liabilities	369
Total current liabilities	554
Non-Current Liabilities:
Asset retirement obligations	306
Other long-term liabilities	588
Total liabilities held for sale	$	1,448

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Asset Retirement Obligations (Tables)

12 Months Ended

Dec. 31, 2022

Asset Retirement Obligation Disclosure [Abstract]

Summary of asset retirement obligations

The following table provides a summary of the changes in the Company’s asset retirement obligations:


(in thousands)	Amount
Balance, January 1, 2022	$	20,833
Change in useful life estimate	280
Accretion expense	1,430
Balance, December 31, 2022	$	22,543

Intangibles, Net and Goodwill (Tables)

12 Months Ended

Dec. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangibles

Intangibles, net, consisted of the following:


	December 31, 2022
(in thousands)	Useful Lives (in years)	Amortization Method	Cost		Accumulated Amortization		Net
Trademarks	15 - 25	Straight-Line	$	13,540	$	(12,061)	$	1,479
Customer relationships	15 - 25	Accelerated	96,681		(95,009)		1,672
Currently marketed product	9 - 15	Straight-Line	275,700		(47,628)		228,072
Licenses	11 - 16	Straight-Line	85,800		(19,101)		66,699
Developed technology	9	Straight-Line	2,400		(677)		1,723
IPR&D	N/A	N/A	15,640		—		15,640
Total			$	489,761	$	(174,476)	$	315,285


	December 31, 2021
(in thousands)	Useful Lives (in years)	Amortization Method	Cost		Accumulated Amortization		Net
Trademarks	15 - 25	Straight-Line	$	13,540	$	(11,510)	$	2,030
Customer relationships	15 - 25	Accelerated	96,880		(94,630)		2,250
Currently marketed product	15	Straight-Line	275,700		(23,345)		252,355
Licenses	11 - 16	Straight-Line	85,800		(11,555)		74,245
Developed technology	9	Straight-Line	2,400		(410)		1,990
IPR&D	N/A	N/A	15,640		—		15,640
Total			$	489,960	$	(141,450)	$	348,510

Schedule of Indefinite-Lived Intangible Assets

Intangibles, net, consisted of the following:


	December 31, 2022
(in thousands)	Useful Lives (in years)	Amortization Method	Cost		Accumulated Amortization		Net
Trademarks	15 - 25	Straight-Line	$	13,540	$	(12,061)	$	1,479
Customer relationships	15 - 25	Accelerated	96,681		(95,009)		1,672
Currently marketed product	9 - 15	Straight-Line	275,700		(47,628)		228,072
Licenses	11 - 16	Straight-Line	85,800		(19,101)		66,699
Developed technology	9	Straight-Line	2,400		(677)		1,723
IPR&D	N/A	N/A	15,640		—		15,640
Total			$	489,761	$	(174,476)	$	315,285


	December 31, 2021
(in thousands)	Useful Lives (in years)	Amortization Method	Cost		Accumulated Amortization		Net
Trademarks	15 - 25	Straight-Line	$	13,540	$	(11,510)	$	2,030
Customer relationships	15 - 25	Accelerated	96,880		(94,630)		2,250
Currently marketed product	15	Straight-Line	275,700		(23,345)		252,355
Licenses	11 - 16	Straight-Line	85,800		(11,555)		74,245
Developed technology	9	Straight-Line	2,400		(410)		1,990
IPR&D	N/A	N/A	15,640		—		15,640
Total			$	489,960	$	(141,450)	$	348,510

Schedule of expected future amortization expense

The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:


(in thousands)	Amount
2023	$	32,638
2024	32,563
2025	32,508
2026	32,497
2027	32,482
2028 and thereafter	136,957
Total	$	299,645

Schedule of goodwill

Changes in the carrying amounts of goodwill for the years ended December 31, 2022 and 2021, were as follows:


	December 31,
(in thousands)	2022		2021
Balance, Beginning of year	$	61,189	$	58,632
Increase from acquisition	—		2,557
Balance, End of year	$	61,189	$	61,189

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Tables)

12 Months Ended

Dec. 31, 2022

Payables and Accruals [Abstract]

Schedule of accrued expenses

Accrued expenses and other liabilities and other long-term liabilities are comprised of the following:


	December 31,
(in thousands)	2022		2021
Compensation and benefits	$	30,425	$	22,730
Freight, distribution and operations	49,067		16,157
Accrued rebates, discounts and chargebacks	13,399		10,977
Accrued professional fees	8,668		2,850

Other	25,525		5,354
Total accrued expenses and other liabilities	$	127,084	$	58,068

Operating lease liabilities (Note 17)	$	25,442	$	16,546
Long-term contingent liability (Note 4)	11,900		86,200
Other long-term liabilities	8,813		22,148
Total other long-term liabilities	$	46,155	$	124,894

Long-Term Debt, Net, and Other Borrowings (Tables)

12 Months Ended

Dec. 31, 2022

Debt Disclosure [Abstract]

Schedule of maturities of principal obligations

As of December 31, 2022, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:


(in thousands)	Amount
2023	$	—
2024	—
2025	—
2026	—
2027	575,000
Total principal outstanding	575,000

Unamortized debt issuance costs	(17,519)
Finance lease liabilities	585
Total	558,066
Less: current portion	(354)
Total long-term debt, net, and other borrowings	$	557,712

Schedule of total net leverage ratio

The maximum total net leverage ratio permitted by the financial covenant is displayed in the table below:

2022 Credit Agreement


Period			Total Net Leverage Ratio
Q1 2023 to Q4 2023			4.00 to 1.00
Q1 2024 and thereafter			3.50 to 1.00

Derivative Instruments (Tables)

12 Months Ended

Dec. 31, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of derivatives instruments

The following table presents the location and fair value amounts of derivative instruments reported in the consolidated balance sheet:

(in thousands)

December 31, 2022

December 31, 2021

Derivatives type

Classification

Assets:

Interest rate swap

Other long-term assets

—

357

Accumulated Other Comprehensive Loss (Tables)

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Schedule of accumulated other comprehensive loss

The components of Accumulated Other Comprehensive Loss, net of tax of zero and $0.1 million for the year ended December 31, 2022 and 2021, respectively, consisted of the following:


(in thousands)	Foreign currency translation		Unrealized loss on cash flow hedges		Accumulated other comprehensive loss
Balance at January 1, 2022	$	(754)	$	269	$	(485)
Other comprehensive income (loss) before reclassifications	(505)		5,838		5,333
Amounts reclassified to earnings	—		(6,107)		(6,107)
Balance at December 31, 2022	$	(1,259)	$	—	$	(1,259)

Balance at January 1, 2021	$	(630)	$	(1,418)	$	(2,048)
Other comprehensive income (loss) before reclassifications	(124)		962		838
Amounts reclassified to earnings	—		725		725
Balance at December 31, 2021	$	(754)	$	269	$	(485)

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of stock-based compensation expense recognized

Stock-based compensation expense recognized in the consolidated statements of operations is summarized below:


	Year Ended December 31,
(in thousands)	2022		2021		2020
Cost of goods sold	$	4,422	$	2,370	$	2,820
Sales and marketing	6,185		2,472		1,821
General and administrative	14,876		9,092		7,333
Research and development	3,779		2,000		2,101
Total stock-based compensation expense	$	29,262	$	15,934	$	14,075

Schedule of option activity

A summary of option activity for 2022 is presented below:


	Total Stock Options	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Balance at January 1, 2022	972,939	$	18.73	4.7	10,145,135
Options granted	317,789	$	53.55
Options exercised	(397,822)	$	20.07
Options cancelled and forfeited	(18,157)	$	38.20
Outstanding at December 31, 2022	874,749	$	30.37	5.8	19,058,224
Vested and expected to vest at December 31, 2022	874,749	$	30.37	5.8	19,058,224
Exercisable at December 31, 2022	517,424	$	17.83	3.6	17,141,202

Schedule of valuation model

The table below summarizes the key weighted-average assumptions used in valuing stock options granted:


	Year Ended December 31,
	2022		2021		2020
Expected volatility	62.1	%	—	%	71.1	%
Risk-free interest rate	2.0	%	—	%	0.3	%
Expected life (in years)	6.0		—		3.5
Expected dividend yield	—		—		—

Summary of restricted stock awards activity

A summary of restricted stock awards and restricted stock units activity for 2022 is presented below:


	Shares	Weighted- Average Grant Date Fair Value Per Share
Nonvested balance at January 1, 2022	1,330,374	$	19.04
Granted	649,672	$	51.51
Vested	(624,069)	$	19.11
Forfeited	(105,985)	$	30.81
Nonvested balance at December 31, 2022	1,249,992	$	34.65

A summary of TSR Award activity for 2022 is presented below:


	Shares	Weighted- Average Grant Date Fair Value Per Share
Nonvested balance at January 1, 2022	590,073	$	30.49
Granted	304,212	$	95.31
Vested	(220,339)	$	39.92
Forfeited	(15,071)	$	31.30
Nonvested balance at December 31, 2022	658,875	$	48.58

Schedule of RSU valuation model

The fair value of these awards are based on a Monte Carlo simulation valuation model with the following assumptions:


	Year Ended December 31,
	2022		2021		2020
Expected volatility	56.6	%	54.0	%	53.3	%
Risk-free interest rate	1.7	%	0.3	%	0.7	%
Expected life (in years)	2.8		2.8		2.8
Expected dividend yield	—		—		—

Leases (Tables)

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Schedule of operating and finance lease assets and liabilities

Operating and finance lease assets and liabilities are as follows:


(in thousands)	Classification	December 31, 2022		December 31, 2021
Assets
Operating	Other long-term assets	$	19,033	$	8,788
Finance	Property, plant and equipment, net	582		556
Total leased assets		$	19,615	$	9,344
Liabilities
Current
Operating	Accrued expenses and other liabilities	$	2,177	$	1,599
Finance	Current portion of long-term debt and other borrowings	354		392
Noncurrent
Operating	Other long-term liabilities	25,442		16,546
Finance	Long-term debt, net and other borrowings	231		299
Total leased liabilities		$	28,204	$	18,836

Schedule of components of lease expense and other information

The components of lease expense were as follows:


(in thousands)	Year Ended December 31, 2022		Year Ended December 31, 2021
Operating lease expense	$	1,797	$	2,312
Finance lease expense
Amortization of ROU assets	426		330
Interest on lease liabilities	28		28
Short-term lease expense	—		8
Total lease expense	$	2,251	$	2,678

Other information related to leases were as follows:


		December 31, 2022		December 31, 2021
Weighted-average remaining lease term (Years):
Operating leases		7.9		8.6
Finance leases		1.9		2.2
Weighted-average discount rate:
Operating leases		4.8%		4.4%
Finance leases		4.4%		4.6%

(in thousands)		Year Ended December 31, 2022		Year Ended December 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	2,440	$	2,071
Operating cash flows from finance leases		28		28
Financing cash flows from finance leases		384		339
ROU assets obtained in exchange for lease obligations:
Operating leases		11,019		683
Finance leases		582		556

Schedule of future minimum lease payments under operating leases

Future minimum lease payments under non-cancellable leases as of December 31, 2022 were as follows:


(in thousands)	Operating Leases		Finance Leases
2023	$	3,462	$	366
2024	3,887		203
2025	4,147		49
2026	4,245		—
2027	4,381		—
Thereafter	13,599		—
Total future minimum lease payments	33,721		618
Less: interest	6,102		33
Total	$	27,619	$	585

Schedule of future minimum lease payments under finance leases

Future minimum lease payments under non-cancellable leases as of December 31, 2022 were as follows:


(in thousands)	Operating Leases		Finance Leases
2023	$	3,462	$	366
2024	3,887		203
2025	4,147		49
2026	4,245		—
2027	4,381		—
Thereafter	13,599		—
Total future minimum lease payments	33,721		618
Less: interest	6,102		33
Total	$	27,619	$	585

Other Assets (Tables)

12 Months Ended

Dec. 31, 2022

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Other Assets

Other assets are comprised of the following:


	December 31,
(in thousands)	2022		2021
Prepaid Expenses	$	12,887	$	10,113
Current Contingent Asset (Note 4)	—		2,500
Other Current Assets	205		205
Total other current assets	$	13,092	$	12,818

ROU Asset (Note 17)	$	19,033	$	8,788
Long-term Contingent Asset (Note 4)	—		6,800
Other Long-Term Assets	15,322		23,170
Total other long-term assets	$	34,355	$	38,758

Net Income (Loss) Per Common Share (Tables)

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Summary of net income (loss) per common share

A summary of net income (loss) per common share is presented below:


	Year Ended December 31,
(in thousands, except per share amounts)	2022		2021		2020
Net income (loss)	$	28,067	$	(71,279)	$	(13,473)

Basic weighted-average common shares outstanding	68,487		67,486		54,134
Effect of dilutive stock options	439		—		—

Effect of dilutive restricted stock	1,745		—		—
Diluted weighted-average common shares outstanding	70,671		67,486		54,134

Basic income (loss) per common share	$	0.41	$	(1.06)	$	(0.25)
Diluted income (loss) per common share	$	0.40	$	(1.06)	$	(0.25)

Antidilutive securities excluded from diluted net income (loss) per common share	358		2,893		3,175

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Schedule of future payments required

As of December 31, 2022, future payments required under purchase commitments are as follows:


(in thousands)	Amount
2023	5,716
2024	2,716
2025	2,716
2026	2,716
2027 and thereafter	2,716
Total	$	16,580

Description of Business (Details) $ / shares in Units, $ in Thousands	Feb. 20, 2020 USD ($) contingent_value_right $ / shares shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($) $ / shares	Jun. 19, 2020 USD ($)
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) \| $ / shares		$ 0.01	$ 0.01
Contingent consideration liabilities		$ 111,600	$ 86,200
Business combination, consideration transferred, equity interests issued (in shares) \| shares	26,844,877
Business combination common stock under contingent value right (in shares) \| shares	86,630,633
Progenics
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) \| $ / shares	$ 0.0013
Progenics
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01
Shares to be received from acquisition conversion (in shares) \| shares	0.31
Number of CVRs \| contingent_value_right	1
Aggregate cash payments percentage	40.00%
Contingent consideration liabilities				$ 3,700
Percentage of total consideration	19.90%
Business combination contingent value right of total consideration	$ 99,700
Progenics \| Cash Payments, 2022
Business Acquisition [Line Items]
Contingent consideration liabilities	100,000
Progenics \| Cash Payments, 2023
Business Acquisition [Line Items]
Contingent consideration liabilities	$ 150,000

Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Capitalized inventories			$ 6.1
Measurement period adjustment	$ 2.6
2.625% Convertible Senior Notes due 2027 \| Senior Notes
Debt Instrument [Line Items]
Interest rate		2.625%

Summary of Significant Accounting Policies - Concentration of Risk and Limited Suppliers (Details) - Revenue Benchmark - Product Concentration Risk	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
PYLARIFY
Concentration Risk [Line Items]
Concentration risk percentage	56.40%	10.20%	0.00%
DEFINITY
Concentration Risk [Line Items]
Concentration risk percentage	26.20%	54.70%	62.80%
TechneLite
Concentration Risk [Line Items]
Concentration risk percentage	9.50%	21.50%	25.40%

Summary of Significant Accounting Policies - Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2022
Buildings \| Minimum
Property, Plant & Equipment [Line Items]
Estimated useful lives	10 years
Buildings \| Maximum
Property, Plant & Equipment [Line Items]
Estimated useful lives	50 years
Land improvements \| Minimum
Property, Plant & Equipment [Line Items]
Estimated useful lives	15 years
Land improvements \| Maximum
Property, Plant & Equipment [Line Items]
Estimated useful lives	40 years
Machinery and equipment \| Minimum
Property, Plant & Equipment [Line Items]
Estimated useful lives	3 years
Machinery and equipment \| Maximum
Property, Plant & Equipment [Line Items]
Estimated useful lives	15 years
Furniture and fixtures
Property, Plant & Equipment [Line Items]
Estimated useful lives	15 years
Leasehold improvements
Property, Plant & Equipment [Line Items]
Estimated useful lives	15 years
Computer software \| Minimum
Property, Plant & Equipment [Line Items]
Estimated useful lives	3 years
Computer software \| Maximum
Property, Plant & Equipment [Line Items]
Estimated useful lives	5 years

Summary of Significant Accounting Policies - Goodwill (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Goodwill, impairment loss	$ 0	$ 0	$ 0

Summary of Significant Accounting Policies - Advertising and Promotion Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Advertising and promotion costs	$ 26.0	$ 17.5	$ 5.2

Summary of Significant Accounting Policies - Stock Based Compensation (Details)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Expected dividend yield	0.00%

Summary of Significant Accounting Policies - Other Loss (Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Foreign currency losses (gains)	$ 256	$ 274	$ 260
Tax indemnification expense (income), net	9,554	7,121	(2,218)
Interest income	(2,613)	(45)	(238)
Interest rate swap termination	(5,494)	0	0
Other	0	0	(2)
Total other loss (income)	$ 1,703	$ 7,350	$ (2,198)

Summary of Significant Accounting Policies - Self-Insurance Reserves (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Accrued liabilities associated with employee medical costs	$ 0.9	$ 0.7

Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Total revenues		$ 935,061	$ 425,208	$ 339,410
Total amount awarded	$ 24,000
Product revenue, net
Disaggregation of Revenue [Line Items]
Total revenues		887,038	400,356	327,695
License and royalty revenues
Disaggregation of Revenue [Line Items]
Total revenues		48,023	24,852	11,715
Total precision diagnostics
Disaggregation of Revenue [Line Items]
Total revenues		356,682	351,025	317,634
DEFINITY
Disaggregation of Revenue [Line Items]
Total revenues		244,993	232,759	195,865
TechneLite
Disaggregation of Revenue [Line Items]
Total revenues		88,864	91,293	84,945
Other precision diagnostics
Disaggregation of Revenue [Line Items]
Total revenues		22,825	26,973	36,824
Total radiopharmaceutical oncology
Disaggregation of Revenue [Line Items]
Total revenues		531,507	48,887	10,022
PYLARIFY
Disaggregation of Revenue [Line Items]
Total revenues		527,405	43,414	0
Other radiopharmaceutical oncology
Disaggregation of Revenue [Line Items]
Total revenues		4,102	5,473	10,022
Strategic Partnerships and other revenue
Disaggregation of Revenue [Line Items]
Total revenues		$ 46,872	$ 25,296	$ 11,754

Revenue from Contracts with Customers - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)
Revenue from Contract with Customer [Abstract]
Total amount awarded	$ 24.0

Revenue from Contracts with Customers - Contract Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Payment terms	standard payment terms are 30 to 60 days
Amounts included in the contract liability at the beginning of the period	$ 244	$ 33

Revenue from Contracts with Customers - Rebates and Allowances (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	$ 10,977	$ 9,350
Provision related to current period revenues	26,683	25,772
Adjustments relating to prior period revenues	70	14
Payments or credits made during the period	(24,331)	(24,159)
Ending Balance	$ 13,399	$ 10,977

Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable		$ 9,300
Total assets	$ 342,646	49,797
Contingent consideration liabilities	111,600	86,200
Total liabilities	111,600	86,200
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable		0
Total assets	342,646	40,140
Contingent consideration liabilities	0	0
Total liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable		0
Total assets	0	357
Contingent consideration liabilities	0	0
Total liabilities	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable	0	9,300
Total assets	0	9,300
Contingent consideration liabilities	111,600	86,200
Total liabilities	111,600	86,200
Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps		357
Interest rate swaps \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps		0
Interest rate swaps \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps		357
Interest rate swaps \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps		0
Money market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	342,646	40,140
Money market \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	342,646	40,140
Money market \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	0	0
Money market \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	$ 0	$ 0

Fair Value of Financial Instruments - Narrative (Details) $ in Thousands		12 Months Ended
	Feb. 20, 2020 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jun. 19, 2020 USD ($)
Fair Value, Option, Quantitative Disclosures [Line Items]
Revenues		$ 935,061	$ 425,208	$ 339,410
Contingent consideration liabilities		111,600	86,200
Change in fair value of the contingent financial asset and contingent financial liabilities		$ 34,700
Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]		General and administrative
Level 3
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities		$ 111,600	86,200
1095 commercialization milestone \| Level 3
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities		$ 1,700	$ 1,900
Royalties \| Level 3 \| Probability of success \| Probability adjusted discounted cash flow model
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input		0
Royalties \| Level 3 \| Probability of success \| Probability adjusted discounted cash flow model \| Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input			0.10
Royalties \| Level 3 \| Probability of success \| Probability adjusted discounted cash flow model \| Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input			0.60
Progenics Pharmaceuticals
Fair Value, Option, Quantitative Disclosures [Line Items]
Royalty percentage		0.05
Potential payments, high		$ 85,000
Progenics Pharmaceuticals \| Net Sales Targets For Azedra
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high		70,000
Progenics Pharmaceuticals \| 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high		5,000
Progenics Pharmaceuticals \| 1404 Commercialization Milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payment not reasonably possible		10,000
Progenics
Fair Value, Option, Quantitative Disclosures [Line Items]
Aggregate cash payments percentage	40.00%
Contingent consideration liabilities					$ 3,700
Progenics \| Current Liabilities
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities		99,700
Progenics \| Cash Payments, 2022
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	$ 100,000
Progenics \| Cash Payments, 2023
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	$ 150,000
Royalty \| Progenics Pharmaceuticals
Fair Value, Option, Quantitative Disclosures [Line Items]
Revenues		$ 5,000

Fair Value of Financial Instruments - Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details) $ in Thousands	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable		$ 9,300
Contingent consideration liabilities	$ 111,600	86,200
Level 3
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	0	9,300
Contingent consideration liabilities	111,600	86,200
Regulatory milestone \| Level 3
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	$ 0	$ 2,500
Regulatory milestone \| Level 3 \| Probability of success \| Probability adjusted discounted cash flow model
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0	0.70
Regulatory milestone \| Level 3 \| Discount rate \| Probability adjusted discounted cash flow model
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input		0.17
Royalties \| Level 3
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	$ 0	$ 6,800
Royalties \| Level 3 \| Probability of success \| Probability adjusted discounted cash flow model
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0
Royalties \| Level 3 \| Probability of success \| Probability adjusted discounted cash flow model \| Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input		0.10
Royalties \| Level 3 \| Probability of success \| Probability adjusted discounted cash flow model \| Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input		0.60
Royalties \| Level 3 \| Discount rate \| Probability adjusted discounted cash flow model
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input		0.17
Net sales targets - PYLARIFY (CVRs) \| Level 3
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	$ 99,700	$ 73,200
Net sales targets - PYLARIFY (CVRs) \| Level 3 \| Probability of success \| Probability adjusted discounted cash flow model (as of 12/31/2022) Monte Carlo simulation (as of 12/31/2021)
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	1
Net sales targets - PYLARIFY (CVRs) \| Level 3 \| Discount rate \| Probability adjusted discounted cash flow model (as of 12/31/2022) Monte Carlo simulation (as of 12/31/2021)
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input		0.17
1095 commercialization milestone \| Level 3
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	$ 1,700	$ 1,900
1095 commercialization milestone \| Level 3 \| Probability of success \| Probability adjusted discounted cash flow model
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.40	0.40
1095 commercialization milestone \| Level 3 \| Discount rate \| Probability adjusted discounted cash flow model
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.038	0.013
Net sales targets - AZEDRA and 1095 \| Level 3
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	$ 10,200	$ 11,100
Net sales targets - AZEDRA and 1095 \| Level 3 \| Probability of success \| Probability adjusted discounted cash flow model (as of 12/31/2022) Monte Carlo simulation (as of 12/31/2021) \| Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.20	0.40
Net sales targets - AZEDRA and 1095 \| Level 3 \| Probability of success \| Probability adjusted discounted cash flow model (as of 12/31/2022) Monte Carlo simulation (as of 12/31/2021) \| Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	1	1
Net sales targets - AZEDRA and 1095 \| Level 3 \| Discount rate \| Probability adjusted discounted cash flow model (as of 12/31/2022) Monte Carlo simulation (as of 12/31/2021) \| Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.16	0.16
Net sales targets - AZEDRA and 1095 \| Level 3 \| Discount rate \| Probability adjusted discounted cash flow model (as of 12/31/2022) Monte Carlo simulation (as of 12/31/2021) \| Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.17	0.17

Fair Value of Financial Instruments - Financial Instruments With Significant Level 3 Inputs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Financial Assets
Fair value, beginning of period	$ 9,300	$ 11,300
Changes in fair value included in net income (loss)	(9,300)	(2,000)
Fair value, end of period	0	9,300
Financial Liabilities
Fair value, beginning of period	86,200	15,800
Changes in fair value included in net income (loss)	25,400	70,400
Fair value, end of period	$ 111,600	$ 86,200
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income Extensible List Not Disclosed Flag	Changes in fair value included in net income (loss)
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement Of Income Extensible List Not Disclosed Flag	Changes in fair value included in net income (loss)

Income Taxes - Schedule of Components of Income Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
U.S.	$ 29,012	$ (76,389)	$ (5,495)
International	(2,293)	1,351	(5,984)
Income (loss) before income taxes	$ 26,719	$ (75,038)	$ (11,479)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Income Taxes - Schedule of (Benefit) Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current
Federal	$ 42,532	$ 0	$ 0
State	4,302	(8,166)	3,158
International	(166)	(30)	170
Current income tax expense (benefit), total	46,668	(8,196)	3,328
Deferred
Federal	(39,920)	1,048	(1,506)
State	(8,315)	3,058	(178)
International	219	331	350
Deferred income tax expense (benefit), total	(48,016)	4,437	(1,334)
Income tax (benefit) expense	$ (1,348)	$ (3,759)	$ 1,994

Income Taxes - Differences in Statutory Rate and Effective Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
U.S. statutory rate	$ 5,611	$ (15,758)	$ (2,411)
Permanent items	2,309	1,764	1,176
Acquisition costs - Progenics	0	0	2,723
Recognition of deferred tax asset - assets held for sale	0	0	(3,000)
Section 162(m)	247	1,028	717
Uncertain tax positions	(12,629)	(8,952)	2,818
Other tax credits	(4,085)	(990)	(1,065)
State and local taxes	67	656	1,457
Impact on deferred taxes of change in tax rate	4,169	3,049	0
Non-deductible changes in fair value of contingent assets and liabilities	5,422	15,015	230
Foreign tax rate differential	68	23	(254)
Valuation allowance	(30)	(400)	(318)
Benefit of windfall related to stock compensation	(4,612)	(1,164)	(128)
Change in indemnification deferred tax asset	2,343	1,786	(590)
Other	(228)	184	639
Income tax (benefit) expense	$ (1,348)	$ (3,759)	$ 1,994

Income Taxes - Components of Deferred Income Tax Assets (Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Assets
Federal benefit of state tax liabilities	$ 1,739	$ 4,292
Reserves, accruals and other	31,532	27,159
Inventory obsolescence	919	297
Capitalized research and development	79,946	768
Amortization of intangibles other than goodwill	0	502
Net operating loss carryforwards	88,014	122,944
Depreciation	0	1,102
Deferred tax assets	202,150	157,064
Deferred Tax Liabilities
Reserves, accruals and other	(5,354)	(3,026)
Intangible assets	(80,770)	(87,351)
Amortization of intangibles other than goodwill	(385)	0
Depreciation	(1,469)	0
Deferred tax liability	(87,978)	(90,377)
Less: valuation allowance	(3,525)	(3,923)
Net deferred tax assets	110,647	62,764
Recorded in the accompanying consolidated balance sheets as:
Noncurrent deferred tax assets, net	$ 110,647	$ 62,764

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Deferred tax asset, valuation allowance	$ 3,525	$ 3,923
Total liabilities for uncertain tax positions including interest and penalties	8,300	20,900
Uncertain tax positions	1,480	3,658	$ 5,292
Interest accruals	6,400	16,500
Penalty accruals	400	800
Tax provision benefit/expense	12,629	8,952	(2,818)
Tax indemnification receivable	3,900	13,500
Tax indemnification expense (income), net	9,554	$ 7,121	$ (2,218)
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryovers	338,400
Operating loss carryforwards expire	200,400
Operating loss carried forward	138,000
State Research Credit
Operating Loss Carryforwards [Line Items]
Net operating loss carryovers	11,600
Tax credits	2,900
Massachusetts \| Investment Tax Credit Carryforward
Operating Loss Carryforwards [Line Items]
Tax credits	$ 1,400

Income Taxes - Reconciliation of Uncertain Tax Positions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of Uncertain Tax Positions [Roll Forward]
Beginning balance of uncertain tax positions	$ 3,658	$ 5,292
Additions related to current year tax positions	0	0
Reductions related to prior year tax positions	(1,180)	(188)
Settlements	(306)	(1,446)
Lapse of statute of limitations	(692)	0
Ending balance of uncertain tax positions	$ 1,480	$ 3,658

Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory [Line Items]
Raw materials	$ 19,987	$ 15,505
Work in process	8,234	13,042
Finished goods	7,254	6,582
Total inventory	$ 35,475	35,129
DEFINITY
Inventory [Line Items]
Total inventory		$ 6,100

Property, Plant & Equipment, Net - Schedule of Property, Plant & Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant & Equipment [Line Items]
Property, plant and equipment, gross	$ 222,294	$ 205,687
Less: accumulated depreciation and amortization	(100,128)	(88,915)
Property, plant and equipment, net	122,166	116,772
Land
Property, Plant & Equipment [Line Items]
Property, plant and equipment, gross	13,450	13,450
Buildings
Property, Plant & Equipment [Line Items]
Property, plant and equipment, gross	76,329	73,559
Machinery, equipment and fixtures
Property, Plant & Equipment [Line Items]
Property, plant and equipment, gross	92,604	83,608
Computer software
Property, Plant & Equipment [Line Items]
Property, plant and equipment, gross	25,864	24,384
Construction in progress
Property, Plant & Equipment [Line Items]
Property, plant and equipment, gross	$ 14,047	$ 10,686

Property, Plant & Equipment, Net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 13.7	$ 13.2	$ 12.5

Business Combinations - Narrative (Details) $ in Thousands		3 Months Ended	12 Months Ended
Business Combinations - Narrative (Details) $ in Thousands	Jun. 19, 2020 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Business Acquisition [Line Items]
Measurement period adjustment		$ 2,600
Goodwill			$ 58,632	$ 61,189	$ 61,189
Progenics
Business Acquisition [Line Items]
Total consideration transferred	$ 419,009
Fair value of bridge loan settled at close	10,074
Measurement period adjustment		$ 2,600
Acquired contingent receivable	10,100
Goodwill	$ 45,475
Acquisition related costs			$ 11,900
Progenics \| Discount rate
Business Acquisition [Line Items]
Measurement input				0.230

Business Combinations - Fair Value of the Consideration Transferred in the Acquisition (Details) - USD ($) $ in Thousands	Jun. 19, 2020	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Contingent consideration liabilities		$ 111,600	$ 86,200
Progenics
Business Acquisition [Line Items]
Issuance of common stock	$ 398,110
Fair value of replacement stock options	7,125
Fair value of bridge loan settled at close	10,074
Contingent consideration liabilities	3,700
Total consideration transferred	$ 419,009

Business Combinations - Assets and Liabilities (Details) - USD ($) $ in Thousands		12 Months Ended
	Jun. 19, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Combination Segment Allocation [Line Items]
Goodwill		$ 61,189	$ 61,189	$ 58,632
Currently marketed product
Business Combination Segment Allocation [Line Items]
Weighted-average useful life			15 years
Developed technology
Business Combination Segment Allocation [Line Items]
Weighted-average useful life		9 years	9 years
Progenics
Business Combination Segment Allocation [Line Items]
Cash and cash equivalents	$ 15,421
Accounts receivable	5,787
Inventory	1,075
Other current assets	3,684
Property, plant and equipment	14,972
IPR&D	151,100
Other long-term assets	37,631
Accounts payable	(1,616)
Accrued expenses and other liabilities	(8,287)
Other long-term liabilities	(31,158)
Long-term debt and other borrowings	(40,200)
Deferred tax liabilities	(5,975)
Goodwill	45,475
Total consideration transferred	419,009
Progenics \| Previously Reported
Business Combination Segment Allocation [Line Items]
Cash and cash equivalents	15,421
Accounts receivable	5,787
Inventory	915
Other current assets	3,250
Property, plant and equipment	14,972
IPR&D	150,900
Other long-term assets	37,631
Accounts payable	(1,616)
Accrued expenses and other liabilities	(8,207)
Other long-term liabilities	(30,778)
Long-term debt and other borrowings	(40,200)
Deferred tax liabilities	(3,717)
Goodwill	42,051
Total consideration transferred	419,009
Progenics \| Revision of Prior Period, Adjustment
Business Combination Segment Allocation [Line Items]
Inventory	160
Other current assets	434
IPR&D	200
Accrued expenses and other liabilities	(80)
Other long-term liabilities	(380)
Deferred tax liabilities	(2,258)
Goodwill	3,424
Total consideration transferred	$ 0
Progenics \| Currently marketed product
Business Combination Segment Allocation [Line Items]
Weighted-average useful life	15 years
Identifiable intangible assets	$ 142,900
Progenics \| Currently marketed product \| Previously Reported
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	142,100
Progenics \| Currently marketed product \| Revision of Prior Period, Adjustment
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ 800
Progenics \| Licenses
Business Combination Segment Allocation [Line Items]
Weighted-average useful life	11 years 6 months
Identifiable intangible assets	$ 85,800
Progenics \| Licenses \| Previously Reported
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	87,500
Progenics \| Licenses \| Revision of Prior Period, Adjustment
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ (1,700)
Progenics \| Developed technology
Business Combination Segment Allocation [Line Items]
Weighted-average useful life	9 years
Identifiable intangible assets	$ 2,400
Progenics \| Developed technology \| Previously Reported
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	3,000
Progenics \| Developed technology \| Revision of Prior Period, Adjustment
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ (600)

Business Combinations - Pro-Forma (Details) $ in Thousands	12 Months Ended
Business Combinations - Pro-Forma (Details) $ in Thousands	Dec. 31, 2020 USD ($)
Business Acquisition [Line Items]
Pro forma revenue	$ 350,315
Pro forma net loss	29,190
Progenics
Business Acquisition [Line Items]
Revenue from acquiree	12,400
Loss from acquiree	$ 27,100

Sale of Puerto Rico Subsidiary - Assets and Liabilities Held for Sale (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2022	Jan. 29, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 0	$ 0		$ 941
Puerto Rican Radiopharmacy Servicing Subsidiary
Non-Current Liabilities:
Pre-tax book gain on disposal	$ 15,300
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Puerto Rican Radiopharmacy Servicing Subsidiary
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase price for stock			$ 18,000
Disposal group holdback amount			1,800
Current assets
Cash and cash equivalents			540
Accounts receivable, net			1,959
Inventory			530
Other current assets			65
Total current assets			3,094
Non-Current Assets:
Property, plant and equipment, net			780
Intangibles, net			96
Other long-term assets			774
Total assets held for sale			4,744
Current liabilities
Accounts payable			185
Accrued expenses and other liabilities			369
Total current liabilities			554
Non-Current Liabilities:
Asset retirement obligations			306
Other long-term liabilities			588
Total liabilities held for sale			$ 1,448

Asset Retirement Obligations - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Asset Retirement Obligation Disclosure [Abstract]
Obligation expected to be incurred	$ 25,100
Change in useful life estimate	280	$ 5,300
Financial assurance in form of surety bond	$ 30,300

Asset Retirement Obligations - Schedule of Reconciliation of Company's Asset Retirement Obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]
Balance at the beginning of the period	$ 20,833
Change in useful life estimate	280	$ 5,300
Accretion expense	1,430
Balance at the ending of the period	$ 22,543	$ 20,833

Intangibles, Net and Goodwill - Schedule of Intangibles, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Oct. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (174,476)	$ (141,450)
Total	299,645
Indefinite lived, cost	15,640	15,640	$ 18,300
Total, cost	489,761	489,960
Total, net	315,285	348,510
Trademarks
Finite-Lived Intangible Assets [Line Items]
Cost	13,540	13,540
Accumulated Amortization	(12,061)	(11,510)
Total	$ 1,479	$ 2,030
Trademarks \| Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	15 years	15 years
Trademarks \| Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	25 years	25 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Cost	$ 96,681	$ 96,880
Accumulated Amortization	(95,009)	(94,630)
Total	$ 1,672	$ 2,250
Customer relationships \| Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	15 years	15 years
Customer relationships \| Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	25 years	25 years
Currently marketed product
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life		15 years
Cost	$ 275,700	$ 275,700
Accumulated Amortization	(47,628)	(23,345)
Total	$ 228,072	252,355
Currently marketed product \| Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	9 years
Currently marketed product \| Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	15 years
Licenses
Finite-Lived Intangible Assets [Line Items]
Cost	$ 85,800	85,800
Accumulated Amortization	(19,101)	(11,555)
Total	$ 66,699	$ 74,245
Licenses \| Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	11 years	11 years
Licenses \| Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	16 years	16 years
Developed technology
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	9 years	9 years
Cost	$ 2,400	$ 2,400
Accumulated Amortization	(677)	(410)
Total	$ 1,723	$ 1,990

Intangibles, Net and Goodwill - Additional Information (Details) $ in Thousands	1 Months Ended	12 Months Ended
	May 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Oct. 31, 2020 USD ($)
Indefinite-lived Intangible Assets [Line Items]
Amortization expense		$ 33,200	$ 27,500	$ 10,800
Indefinite lived, cost		$ 15,640	$ 15,640		$ 18,300
Impairment				$ 2,700
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]				Research and development
IPR & D
Indefinite-lived Intangible Assets [Line Items]
Decrease in indefinite lived assets	$ 132,800
Currently marketed product
Indefinite-lived Intangible Assets [Line Items]
Finite-lived intangible assets, period increase (decrease)	$ 132,800
Discount rate
Indefinite-lived Intangible Assets [Line Items]
Measurement input				0.230

Intangibles, Net and Goodwill - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 32,638
2024	32,563
2025	32,508
2026	32,497
2027	32,482
2028	136,957
Total	$ 299,645

Intangibles, Net and Goodwill - Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Goodwill [Roll Forward]
Beginning of year	$ 61,189	$ 58,632
Increase from acquisition	0	2,557
End of year	$ 61,189	$ 61,189

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Accrued Expenses and Other Liabilities and Other Long-Term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Compensation and benefits	$ 30,425	$ 22,730
Freight, distribution and operations	49,067	16,157
Accrued rebates, discounts and chargebacks	13,399	10,977
Accrued professional fees	8,668	2,850
Other	25,525	5,354
Total accrued expenses and other liabilities	127,084	58,068
Operating lease liabilities	25,442	16,546
Long-term contingent liability	11,900	86,200
Other long-term liabilities	8,813	22,148
Total other long-term liabilities	$ 46,155	$ 124,894

Long-Term Debt, Net, and Other Borrowings - Schedule of Minimum Payments Maturities of Principal Obligations Under Term Facility (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
2023	$ 0
2024	0
2025	0
2026	0
2027	575,000
Total principal outstanding	575,000
Unamortized debt issuance costs	(17,519)
Finance lease liabilities	585
Total	558,066
Less: current portion	(354)	$ (11,642)
Total long-term debt, net, and other borrowings	$ 557,712	$ 163,121

Long-Term Debt, Net, and Other Borrowings - Additional Information (Details)				1 Months Ended		9 Months Ended	12 Months Ended
	Dec. 08, 2022 USD ($) $ / shares	Dec. 05, 2022	Mar. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) financial_covenant	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jun. 19, 2020 USD ($)	Nov. 04, 2016 USD ($)
Debt Instrument [Line Items]
Gain (loss) on extinguishment of debt							$ (588,000)	$ 889,000	$ 0
Number of covenants \| financial_covenant							2
Minimum interest coverage ratio				3.00	3.00		3.00
Debt Instrument, convertible, carrying amount				$ 558,066,000	$ 558,066,000		$ 558,066,000
Convertible Debt
Debt Instrument [Line Items]
Extinguishment of debt, amount	$ 75,000,000
Progenics
Debt Instrument [Line Items]
Debt instrument, face amount											$ 50,000,000
Interest rate											9.50%
Progenics
Debt Instrument [Line Items]
Long-term debt and other borrowings										$ 40,200,000
2.625% Convertible Senior Notes due 2027 \| Convertible Debt
Debt Instrument [Line Items]
Debt instrument, face amount	$ 575,000,000
Interest rate	2.625%
Proceeds from convertible debt	$ 557,800,000
Convertible, conversion ratio		0.0125291		0.0178539
Initial conversion price (in dollars per share) \| $ / shares	$ 79.81
Initial conversion premium	42.50%
Share price (in dollars per share) \| $ / shares	$ 56.01
Debt instrument, stock price percentage	130.00%
Purchase price as a percentage of principal amount	100.00%
Debt Instrument, convertible, carrying amount				$ 575,000,000	575,000,000		575,000,000
Debt instrument, unamortized discount				0	0		0
Debt instrument, fair value				$ 575,000,000	$ 575,000,000		575,000,000
Interest expense, debt							$ 1,300,000
Royalty-Backed Loan
Debt Instrument [Line Items]
Gain (loss) on extinguishment of debt			$ 900,000
Extinguishment of debt, amount			30,900,000
Prepayment of debt, amount			$ 500,000
Minimum \| 2.625% Convertible Senior Notes due 2027 \| Convertible Debt
Debt Instrument [Line Items]
Debt instrument, covenant percentage of additional interest				0.25%	0.25%		0.25%
Maximum \| 2.625% Convertible Senior Notes due 2027 \| Convertible Debt
Debt Instrument [Line Items]
Debt instrument, covenant percentage of additional interest				0.50%	0.50%		0.50%
2019 Term Loan Facility \| Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				$ 200,000,000	$ 200,000,000		$ 200,000,000
Debt instrument, term (in years)							5 years
Repayments of debt					167,600,000	$ 7,800,000
Gain (loss) on extinguishment of debt							$ (600,000)
Deferred financing costs				2,700,000	2,700,000		2,700,000
2019 Revolving Facility \| Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				200,000,000	200,000,000		$ 200,000,000
Debt instrument, term (in years)							5 years
2022 Term Facility \| Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				100,000,000	100,000,000		$ 100,000,000
Line of credit facility, commitment fee percentage							0.20%
Revolving Credit Facility \| Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				350,000,000	350,000,000		$ 350,000,000
Debt instrument, term (in years)							5 years
Outstanding borrowings				0	0		$ 0
Revolving Credit Facility \| Minimum \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate \| Line of Credit
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)							1.50%
Revolving Credit Facility \| Minimum \| Base Rate \| Line of Credit
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)							0.50%
Revolving Credit Facility \| Minimum \| Leverage Ratio Range \| Line of Credit
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage							0.15%
Revolving Credit Facility \| Maximum \| Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				350,000,000	350,000,000		$ 350,000,000
Line of credit facility, accordion feature, higher borrowing capacity option				335,000,000	335,000,000		$ 335,000,000
Revolving Credit Facility \| Maximum \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate \| Line of Credit
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)							2.50%
Revolving Credit Facility \| Maximum \| Base Rate \| Line of Credit
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)							1.50%
Revolving Credit Facility \| Maximum \| Leverage Ratio Range \| Line of Credit
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage							0.35%
Letter of Credit \| Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				20,000,000	20,000,000		$ 20,000,000
Bridge Loan \| Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				$ 10,000,000	$ 10,000,000		$ 10,000,000

Long-Term Debt, Net, and Other Borrowings - Schedule of Net Leverage Ratio (Details) - Amendment 2022 Credit Facility	12 Months Ended
	Dec. 31, 2022
Q1 2023 to Q4 2023
Debt Instrument [Line Items]
Total net leverage ratio	4.00
Q1 2024 and thereafter
Debt Instrument [Line Items]
Total net leverage ratio	3.50

Derivative Instruments (Details) - USD ($) $ in Thousands	12 Months Ended
Derivative Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
Derivative [Line Items]
Proceeds from interest rate swap termination	$ 5,583	$ 0	$ 0
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other long-term assets	Other long-term assets
Interest rate swaps
Derivative [Line Items]
Proceeds from interest rate swap termination	$ 5,600
Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax	$ 5,500
Cash Flow Hedge \| Interest rate swaps
Derivative [Line Items]
Notional amount				$ 100,000
Average fixed interest rate	0.82%
Interest rate swaps	$ 0	$ 357

Accumulated Other Comprehensive Loss (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, tax	$ 0	$ 100,000
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	464,439,000	514,205,000
Other comprehensive income (loss) before reclassifications	5,333,000	838,000
Amounts reclassified to earnings	(6,107,000)	725,000
Ending balance	447,147,000	464,439,000
Foreign currency translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(754,000)	(630,000)
Other comprehensive income (loss) before reclassifications	(505,000)	(124,000)
Amounts reclassified to earnings	0	0
Ending balance	(1,259,000)	(754,000)
Unrealized loss on cash flow hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	269,000	(1,418,000)
Other comprehensive income (loss) before reclassifications	5,838,000	962,000
Amounts reclassified to earnings	(6,107,000)	725,000
Ending balance	0	269,000
Accumulated other comprehensive loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(485,000)	(2,048,000)
Ending balance	$ (1,259,000)	$ (485,000)

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Stock-Based Compensation - Equity Incentive Plans (Details)	Dec. 31, 2022 shares
Share-Based Payment Arrangement [Abstract]
Share based compensation, shares authorized (in shares)	10,930,277

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 29,262	$ 15,934	$ 14,075
Cost of goods sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	4,422	2,370	2,820
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	6,185	2,472	1,821
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	14,876	9,092	7,333
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 3,779	$ 2,000	$ 2,101

Stock-Based Compensation - Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]
Contractual term	10 years
Total Stock Options
Options outstanding, beginning balance (in shares)	972,939
Options granted (in shares)	317,789
Options exercised (in shares)	(397,822)	(318,662)	(8,868)
Options cancelled and forfeited (in shares)	(18,157)
Options outstanding, ending balance (in shares)	874,749	972,939
Exercisable (in shares)	517,424
Weighted- Average Exercise Price
Options outstanding, beginning balance (in dollars per share)	$ 18.73
Options granted (in dollars per share)	53.55
Options exercised (in dollars per share)	20.07
Options cancelled and forfeited (in dollars per share)	38.20
Options outstanding, ending balance (in dollars per share)	30.37	$ 18.73
Exercisable (in dollars per share)	$ 17.83
Weighted- Average Remaining Contractual Term (Years)
Options outstanding, weighted average remaining contractual term (in years)	5 years 9 months 18 days	4 years 8 months 12 days
Exercisable, weighted average remaining contractual term (in years)	3 years 7 months 6 days
Options outstanding, aggregate intrinsic value	$ 19,058,224	$ 10,145,135
Exercisable, aggregate intrinsic value	$ 17,141,202
Options exercised (in shares)	397,822	318,662	8,868
Aggregate intrinsic value	$ 13,100	$ 1,600	$ 100
Unrecognized compensation expense	$ 7,000
Weighted-average remaining period for recognition of unrecognized compensation costs	2 years 2 months 12 days

Stock-Based Compensation - Valuation Model (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Shares
Nonvested beginning balance (in shares)	1,330,374
Granted (in shares)	649,672
Vested (in shares)	(624,069)
Forfeited (in shares)	(105,985)
Nonvested ending balance (in shares)	1,249,992	1,330,374
Weighted- Average Grant Date Fair Value Per Share
Nonvested beginning balance (in dollars per share)	$ 19.04
Granted (in dollars per share)	51.51
Vested (in dollars per share)	19.11
Forfeited (in dollars per share)	30.81
Nonvested, ending balance (in dollars per share)	$ 34.65	$ 19.04
Options exercised (in shares)	397,822	318,662	8,868
Aggregate intrinsic value	$ 13,100,000	$ 1,600,000	$ 100,000
Unrecognized compensation expense	$ 7,000,000
Weighted-average remaining period for recognition of unrecognized compensation costs	2 years 2 months 12 days
Options
Weighted- Average Grant Date Fair Value Per Share
Expected volatility	62.10%	0.00%	71.10%
Risk-free interest rate	2.00%	0.00%	0.30%
Expected life (in years)	6 years		3 years 6 months
Expected dividend yield	$ 0	$ 0	$ 0
Restricted stock
Weighted- Average Grant Date Fair Value Per Share
Granted (in dollars per share)	$ 51.51	$ 20.14	$ 15.00
Fair value of vested shares	$ 11,900,000	$ 8,800,000	$ 7,600,000
Unrecognized compensation expense	$ 30,100,000
Weighted-average remaining period for recognition of unrecognized compensation costs	2 years

Stock-Based Compensation - Total Stockholder Return Restricted Awards (Details) - Total Stockholder Return Restricted Stock Awards - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance awards, measurement period	3 years
Expected volatility	56.60%	54.00%	53.30%
Risk-free interest rate	1.70%	0.30%	0.70%
Expected life (in years)	2 years 9 months 18 days	2 years 9 months 18 days	2 years 9 months 18 days
Expected dividend yield	$ 0	$ 0	$ 0
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentages attainable during period	0.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentages attainable during period	200.00%

Stock-Based Compensation - Summary of TSR Award Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Shares
Nonvested beginning balance (in shares)	1,330,374
Granted (in shares)	649,672
Vested (in shares)	(624,069)
Forfeited (in shares)	(105,985)
Nonvested ending balance (in shares)	1,249,992	1,330,374
Weighted- Average Grant Date Fair Value Per Share
Nonvested beginning balance (in dollars per share)	$ 19.04
Granted (in dollars per share)	51.51
Vested (in dollars per share)	19.11
Forfeited (in dollars per share)	30.81
Nonvested, ending balance (in dollars per share)	$ 34.65	$ 19.04
Unrecognized compensation expense	$ 7,000,000
Weighted-average remaining period for recognition of unrecognized compensation costs	2 years 2 months 12 days
Total Stockholder Return Restricted Stock Awards
Shares
Nonvested beginning balance (in shares)	590,073
Granted (in shares)	304,212
Vested (in shares)	(220,339)
Forfeited (in shares)	(15,071)
Nonvested ending balance (in shares)	658,875	590,073
Weighted- Average Grant Date Fair Value Per Share
Nonvested beginning balance (in dollars per share)	$ 30.49
Granted (in dollars per share)	95.31	$ 31.25	$ 23.43
Vested (in dollars per share)	39.92
Forfeited (in dollars per share)	31.30
Nonvested, ending balance (in dollars per share)	$ 48.58	$ 30.49
Unrecognized compensation expense	$ 18,900,000
Weighted-average remaining period for recognition of unrecognized compensation costs	2 years
Fair value of vested shares	$ 8,800,000	$ 2,000,000	$ 0
Restricted stock
Weighted- Average Grant Date Fair Value Per Share
Granted (in dollars per share)	$ 51.51	$ 20.14	$ 15.00
Vesting period	3 years
Unrecognized compensation expense	$ 30,100,000
Weighted-average remaining period for recognition of unrecognized compensation costs	2 years
Fair value of vested shares	$ 11,900,000	$ 8,800,000	$ 7,600,000

Stock-Based Compensation - Summary Common Stock Repurchases (Details) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized amount	$ 150,000,000	$ 150,000,000
Net proceeds from the notes	$ 75,000,000
Sale of stock, price per share (in dollars per share)	$ 56.01	$ 56.01
Shares repurchased (in shares)		1,300,000	0	0
Repurchase of common stock		$ 75,000,000

Leases - Additional Information (Details) $ in Thousands	12 Months Ended
Leases - Additional Information (Details) $ in Thousands	Dec. 31, 2021 USD ($)	Dec. 31, 2022 USD ($) lease	Oct. 31, 2021 USD ($)	Sep. 30, 2021	Jun. 19, 2020 USD ($)
Lessee, Lease, Description [Line Items]
Number of leases \| lease		2
Operating lease		$ 27,619
Lessor term of contract				9 years
Impairment, lessor asset under operating lease	$ 9,500
New York City
Lessee, Lease, Description [Line Items]
Operating lease					$ 18,600
Somerset, New Jersey
Lessee, Lease, Description [Line Items]
Operating lease			$ 700		$ 600
Bedford, Massachusetts
Lessee, Lease, Description [Line Items]
Operating lease		$ 11,000

Leases - Operating and Financing Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets
Operating	$ 19,033	$ 8,788
Finance	582	556
Total leased assets	19,615	9,344
Current
Operating	2,177	1,599
Finance	354	392
Noncurrent
Operating	25,442	16,546
Finance	231	299
Total leased liabilities	$ 28,204	$ 18,836
Operating lease, right-of-use asset, statement of financial position [Extensible List]	Other long-term assets	Other long-term assets
Finance lease, right-of-use asset, statement of financial position [Extensible List]	Property, plant and equipment, net	Property, plant and equipment, net
Operating lease, liability, current, statement of financial position [Extensible List]	Accrued expenses and other liabilities	Accrued expenses and other liabilities
Finance lease, liability, current, statement of financial position [Extensible List]	Current portion of long-term debt and other borrowings	Current portion of long-term debt and other borrowings
Operating lease, liability, noncurrent, statement of financial position [Extensible List]	Other long-term liabilities	Other long-term liabilities
Finance lease, liability, noncurrent, statement of financial position [Extensible List]	Long-term debt, net and other borrowings	Long-term debt, net and other borrowings

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease expense	$ 1,797	$ 2,312
Finance lease expense
Amortization of ROU assets	426	330
Interest on lease liabilities	28	28
Short-term lease expense	0	8
Total lease expense	$ 2,251	$ 2,678

Leases - Other Information Related to Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Weighted-average remaining lease term (Years):
Operating leases	7 years 10 months 24 days	8 years 7 months 6 days
Finance leases	1 year 10 months 24 days	2 years 2 months 12 days
Weighted-average discount rate:
Operating leases	4.80%	4.40%
Finance leases	4.40%	4.60%
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 2,440	$ 2,071
Operating cash flows from finance leases	28	28
Financing cash flows from finance leases	384	339
ROU assets obtained in exchange for lease obligations:
Operating leases	11,019	683
Finance leases	$ 582	$ 556

Leases - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Operating Leases
2023	$ 3,462
2024	3,887
2025	4,147
2026	4,245
2027	4,381
Thereafter	13,599
Total future minimum lease payments	33,721
Less: interest	6,102
Total	27,619
Finance Leases
2023	366
2024	203
2025	49
2026	0
2027	0
Thereafter	0
Total future minimum lease payments	618
Less: interest	33
Total	$ 585

Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses	$ 12,887	$ 10,113
Current contingent asset	0	2,500
Other Current Assets	205	205
Total other current assets	13,092	12,818
ROU Asset	19,033	8,788
Long-term contingent asset	0	6,800
Other Long-Term Assets	15,322	23,170
Total other long-term assets	$ 34,355	$ 38,758

Net Income (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 08, 2022
Earnings Per Share [Abstract]
Net income (loss)	$ 28,067	$ (71,279)	$ (13,473)
Basic weighted-average common shares outstanding (in shares)	68,487	67,486	54,134
Effect of dilutive stock options (in shares)	439	0	0
Effect of dilutive restricted stock (in shares)	1,745	0	0
Diluted weighted-average common shares outstanding (in shares)	70,671	67,486	54,134
Basic income (loss) per common share (in dollars per share)	$ 0.41	$ (1.06)	$ (0.25)
Diluted income (loss) per common share (in dollars per share)	$ 0.40	$ (1.06)	$ (0.25)
Antidilutive securities excluded from diluted net income (loss) per common share (in shares)	358	2,893	3,175
2.625% Convertible Senior Notes due 2027 \| Convertible Debt
Debt Instrument [Line Items]
Initial conversion price (in dollars per share)				$ 79.81

Commitments and Contingencies - Purchase Commitments Under Noncancelable Arrangements (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2023	$ 5,716
2024	2,716
2025	2,716
2026	2,716
2027 and thereafter	2,716
Total	$ 16,580

Commitments and Contingencies - Additional Information (Details) $ in Millions	Dec. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
License agreements	$ 0.1
Contingent payments	$ 200.0

401(k) Plan (Details) - USD ($) $ in Millions	12 Months Ended
401(k) Plan (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Expense recognized by the company for matching contributions	$ 3.1	$ 2.6	$ 0.8

Acquisition of Assets (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
Acquisition of Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Asset Acquisition [Line Items]
Research and development		$ 311,681	$ 44,966	$ 32,788
POINT Biopharma
Asset Acquisition [Line Items]
Payment for acquisitions	$ 260,000
Asset acquisition, additional milestone payments	1,800,000
Research and development		$ 260,000
PNT2002 License Agreement
Asset Acquisition [Line Items]
Payment for acquisitions	$ 250,000
Royalty percentage	20.00%
PNT2002 License Agreement \| Regulatory Milestones
Asset Acquisition [Line Items]
Asset acquisition, additional milestone payments	$ 281,000
PNT2002 License Agreement \| Sales Milestones
Asset Acquisition [Line Items]
Asset acquisition, additional milestone payments	1,300,000
PNT2003 License Agreement
Asset Acquisition [Line Items]
Payment for acquisitions	$ 10,000
Royalty percentage	15.00%
PNT2003 License Agreement \| Regulatory Milestones
Asset Acquisition [Line Items]
Asset acquisition, additional milestone payments	$ 34,500
PNT2003 License Agreement \| Sales Milestones
Asset Acquisition [Line Items]
Asset acquisition, additional milestone payments	$ 275,000

Segment Information (Details)	12 Months Ended
Segment Information (Details)	Dec. 31, 2022 Segment
Segment Reporting [Abstract]
Number of operating segments	1

Subsequent Event (Details) $ in Millions	Feb. 06, 2023 USD ($)
Subsequent Event \| Cerveau Technologies, Inc
Subsequent Event [Line Items]
Acquisition of assets	$ 35